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“There is an art, it says, or rather, a knack to flying. The knack lies in learning how to throw 
yourself at the ground and miss.” 
Douglas Adams, Life, the Universe and Everything (1982) 
 

  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Kroppen är uppbyggd av tiotals biljoner celler som alla har sitt ursprung i det befruktade ägget. 
Nya celler bildas under fostertiden via celldelning och cellerna specialiseras under utvecklingens 
gång för att bilda de ca 200 olika celltyper som kroppen består av. De flesta av cellerna i den 
vuxna kroppen kan inte dela på sig för att bilda nya celler. Dom är specialiserade och anpassade 
att utföra en viss uppgift och kan antingen vara långlivade, som hjärnceller, eller kortlivade, som 
cellerna i mag-tarmkanalen och huden. Celler som är kortlivade, slits och behöver bytas ut. Nya 
celler bildas av stamceller som finns i de flesta av våra vävnader, men som utgör endast en liten 
del av dessa. Stamceller har den unika förmågan att kunna dela på sig för att skapa nya 
specialiserade celler och samtidigt kunna skapa nya stamceller.  
Stamceller ser olika ut och deras egenskaper skiljer sig åt i olika vävnader. Till vilken grad 
stamceller från olika vävnader använder sig av samma mekanismer för att bibehålla 
stamcellsfunktion och identitet är något som vi har tittat närmare på i denna avhandling. SOX är 
namnet på en familj av transkriptionsfaktorer dvs. protein som kan binda till arvsmassan (DNA) 
för att bestämma vilka gener som ska vara aktiva eller inte. Vi har funnit att SOX2, som finns i 
stamceller från flera olika vävnader, binder till gener som är aktiva gemensamt i dessa celler, men 
framförallt till gener som är aktiva specifikt i de olika stamcellstyperna. Detta kan verka 
förvånande eftersom SOX2 binder till samma sekvens (DNA-kod) i arvsmassan i alla 
stamcelltyper. SOX2-bindning till arvsmassan styrs därför troligtvis med hjälp av cellspecifika 
partnerfaktorer, vilket också är vad vår analys tyder på. SOX2 som binder till arvsmassan kan i 
samarbete med andra transkriptionsfaktorer styra aktiviteten av specifika gener i dessa olika 
stamcellstyper. En gemensam funktion som är beroende av SOX2 i alla olika stamcellstyper, och 
som vi studerat närmare, är hur ofta stamcellerna delar på sig för att skapa nya celler. 
Alla celler som har förmågan att dela på sig i kroppen utgör också en risk för cancerutveckling. 
Varje gång en cell delar på sig så måste arvsmassan kopieras. Denna process är inte felfri och 
mutationer, felskrivningar, i arvsmassan kan uppstå vid celldelning, och dessa går i arv till alla nya 
celler som bildas från den specifika stamcellen som felet uppstod i. Mutationer som uppstår i 
vissa gener, onkogener eller tumörsuppressorer, är särskilt allvarliga. Dessa kan leda till ökad 
celldelning, men också till minskad celldöd, som annars är en av kroppens försvarsmekanismer 
för att bli av med tumörbildande celler. Kroppen har välstuderade försvarsmekanismer mot 
tumörbildande celler, men hur dessa kan aktiveras efter uppkomsten av tumörframkallande 
mutationer specifikt i stamceller är fortfarande oklart. Vi har tittat närmare på stamceller i 
hjärnan och i magsäcken och funnit att medlemmar av SOX-familjen som är aktiva i dessa celler 
kan reagera på tumörframkallande mutationer och starta försvarsmekanismer för att blockera 
cancerväxt. 
Tillsammans visar våra data på viktiga funktioner för SOX-familjen i regleringen av stamceller 
under utvecklingen samt för skyddet av stamceller vid ett cancerhot. Vikten av en djupare 
förståelse för stamceller generellt och för uppkomsten och utvecklingen av cancer är stor för att 
kunna finna nya sätt och mediciner att behandla denna sjukdom. 

  
ABSTRACT 
As stem cells are needed not only to build our bodies during development, but also to maintain 
tissue function during adulthood, it is of great importance to the organism to maintain their 
integrity. However, stem cells also pose a threat, as oncogenic mutations can transform them or 
their progeny to malignant cells giving rise to cancer. Many SOX members have been defined as 
master regulators of stem cell maintenance, cell fate specification and differentiation. How SOX 
factors regulate stem cell function across different lineages and also how they can contribute to 
disease protection following oncogenic insult are key questions in this thesis. 
In Paper I we investigate how SOX2 can regulate both cell type specific and common features 
of stem cells from four different tissues of two germ layers. Using ChIP-seq and RNA-seq 
analysis we find that although SOX2 binds some common targets, SOX2 binding is mostly cell 
type specific. This specificity coincides with motif enrichment of common or cell type specific 
transcription factors. We further show that SOX2 can interact with, and functionally regulate 
gene expression together with these transcription factors. Moreover, we also find that isolated 
peak regions can act as cis-regulatory modules (CRMs) to activate germ layer specific and 
common expression in zebrafish.  
In Paper II we ask how adult stem cells of the brain can evade oncogenic transformation and 
elicit an appropriate tumor suppressor response. We find that the functionally related SOX5, 
SOX6 and SOX21 (SOX5/6/21) are induced in neural stem cells after oncogenic expression, 
and that this upregulation is required for the cells to repress tumor development. We also 
demonstrate that the expression levels of SOX5/6/21 are significantly lower in human tissue 
from highly malignant glioma compared to glioma of lower malignancy grade, and that re-
establishing SOX5/6/21 expression in human glioma cells leads to a re-gain in tumor suppressor 
function and response. We further show that these functional characteristics are at least in part 
dependent on the ability of SOX21 to stabilize the protein levels of the tumor suppressor p53. 
In Paper III we expand on the findings demonstrated in Paper II and ask whether stem cells of 
different origins and with different characteristics use SOX21 in a similar manner to establish 
protection from oncogenic transformation. Using the stomach as a model system, we find stem 
cell expression of SOX21 in both mouse and human tissue, and that the SOX21 mRNA levels 
are significantly downregulated in human gastric cancer compared to normal tissue. By 
overexpressing SOX21 in human gastric cancer cell lines, we find that proliferation decreases and 
apoptosis is induced, but only in cell lines expressing p53. We further show that wt p53 levels are 
increased after SOX21 expression and we speculate that this could at least in part be responsible 
for the increase in the anti-tumorigenic response. 
Together, the work in this thesis highlights SOX transcription factors as important regulators of 
the vastly different but connected processes of stem cell maintenance and stem cell protection. 
Performing these functions SOX proteins use both their well-studied ability to bind and regulate 
gene expression together with partner factors, but also an ability to bind and affect proteins at a 
post-translational level. 
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1 INTRODUCTION 
Stem cells are essential to our lives. From the totipotent stem cells present in the earliest embryo 
just after the fertilization of the egg, to the pluripotent and multipotent stem cells building the 
body during embryonic development. As adults, we depend on organ specific stem cells and 
without them our bodies would deteriorate, some organs even within days, and death would be 
certain (Arnold et al., 2011). Ageing, characterized by diminishing organ function and declining 
regeneration (repair), is in part due to a malfunctioning stem cell compartment (Rando, 2006). 
But stem cells also constitute an inherent threat to our organism. Any actively proliferating cell 
will incorporate errors during DNA replication that will be passed down to all daughter cells 
generated. Adult stem cells accumulate mutations at a steady rate, about 36 per cell and year 
(Blokzijl et al., 2016), and when mutations appear in genes important for cell cycle regulatory 
functions it can give rise to cells with growth advantages and with the ability to expand at the 
expense of others. When enough severe mutations have accumulated, hyperplasia and cancer will 
arise (Curtius et al., 2018). 
Because of their importance, the regulation of stem cell function has to be precise. How this is 
achieved, in stem cells of different origins, and how adult stem cells protect themselves from 
oncogenic transformation are two questions central to this thesis. We have addressed them in the 
context of SOX transcription factors as we have examined their roles in development and 
disease. 
1.1 STEM CELLS AND DEVELOPMENT FROM A SOX PERSPECTIVE 
Stem cells, as the name suggests, are the stem from which other cell types emerge, and this is one 
of two defining characteristics. The other characteristic is the maintenance of their own identity 
and potential after mitosis, known as self-renewal. There are several types of stem cells, with 
varying potency, ranging from totipotent to unipotent. Cells from the pre-implantation zygote up 
to the morula stage are totipotent, meaning that they are able to generate all cells within the 
embryo and in addition all the extraembryonic tissues. Cells from the inner cell mass of the 
blastocyst are pluripotent and can give rise to all cells within the embryo, but contributes only 
marginally to the extraembryonic tissues. Finally, further down the developmental cascade 
multipotent stem cells in different locations give rise to all the specific organs of the animal, and 
in the adult, both multipotent and unipotent stem cells produce differentiated progeny to 
maintain organ homeostasis and to repair tissue damage (De Los Angeles et al., 2015). 
Multiple transcriptional networks and signaling pathways, including FGF, BMP, WNT, SHH and 
NOTCH are instrumental for the coordination of the developmental program (Briscoe, 2009; 
Louvi and Artavanis-Tsakonas, 2006; Merrill, 2012; Thisse and Thisse, 2005; Zhang and Li, 
2005). One group of transcription factors (TFs) with important developmental functions, often 
interacting with theses signaling pathways both genetically and physically, is the SOX family 
(Sarkar and Hochedlinger, 2013). The SOX (Sry box containing protein) proteins constitute an 
ancient family of TFs present in all metazoans, with some evidence suggesting that they might 
even predate multicellularity (Bowles et al., 2000; Guth and Wegner, 2008; Wilson and 
Dearden, 2008). They bind DNA in a motif specific manner, but rely mainly on co-binding of 
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partner factors for cell specific DNA binding (Kondoh and Kamachi, 2009), which make them 
versatile and highly adaptable to influence multiple processes in a wide variety of cell types. 
1.1.1 Pluripotent stem cells 
The first SOX factor to be expressed during development is SOX2, which is present already in 
the zygote being translated from maternal mRNA. Early embryonic expression of SOX2 is 
crucial for the epiblast and the extraembryonic endoderm and targeted embryos die shortly after 
implantation, whereas zygotes depleted for maternal Sox2 mRNA arrest already at the morula 
stage (Avilion et al., 2003; Keramari et al., 2010). After the first lineage specification in the 
embryo, creating the inner cell mass (ICM) and the outer trophoectoderm (TE) of the blastocyst, 
the expression of SOX2 becomes mostly restricted to the ICM, being expressed only in a subset 
of cells of the TE (Cockburn and Rossant, 2010; Keramari et al., 2010). SOX2 binds to the 
FGF4 enhancer and induces its expression, which is important for the survival and development 
of the surrounding TE, which express the receptor FGFR2 (Rossant and Cross, 2001; Yuan et 
al., 1995). 
Pluripotent embryonic stem cells (ESC) can be isolated from the ICM of the blastocyst and be 
indefinitely propagated in vitro as self-renewing undifferentiated cells that retain the potential to 
differentiate into any cell of the body upon receiving the appropriate cues (De Los Angeles et al., 
2015; Martello and Smith, 2014). Central to the transcriptional network maintaining 
pluripotency are the core transcription factors OCT4 and NANOG together with SOX2. 
Together they bind enhancers and promoters, including their own, to activate expression causing 
a feed forward loop stabilizing the expression of pluripotency genes (Boyer et al., 2005). In 
addition, SOX2, OCT4 and NANOG also cooperatively bind and repress other promoters and 
enhancers, especially those whose expression induce differentiation along the different germ 
layers, thus keeping these genes in an inactive, yet ready state (Bernstein et al., 2006; Boyer et al., 
2005; Lee et al., 2006). SOX2 by itself is necessary to maintain self-renewal and pluripotency, 
mainly through the induction of OCT4. ESCs cannot be established from SOX2 deficient ICM 
and already established ESCs depleted for SOX2 will undergo differentiation towards the TE 
lineage (Masui et al., 2007). Furthermore, the levels of SOX2 and OCT4 need to be kept within 
a precise range, as an increase in SOX2 will also lead to differentiation and an increase in SOX21, 
further pushing the cells down the ectodermal, mesodermal and TE lineage (Mallanna et al., 
2010). 
Trophoblast stem cells (TSCs) can be isolated from the embryo at a similar stage as ESCs but are 
derived from the TE rather than the ICM. As a close yet distinct lineage, these cells can also be 
kept as self-renewing cells in vitro and can be differentiated into multiple lineages (Latos and 
Hemberger, 2014). Whereas SOX2 is also essential for the self-renewal of these cells, it is 
interesting to note that the DNA binding profile of SOX2 differ extensively between TSCs and 
ESCs. While SOX2 interacts with OCT4 in ESCs to activate target gene expression, SOX2 
interacts and binds together with TFAP2C in TSC to regulate a different set of targets. Thus, 
although activating a small set of common targets important for self-renewal in both cells types, 
SOX2 exhibits its functions in a largely cell specific manner, by interacting with cell specific co-
factors (Adachi et al., 2013). Apart from SOX2, SOX17 is an important factor establishing TSC, 
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suppressing the alternative ICM cell fate by counteracting NANOG at SOX2/OCT4/NANOG 
bound enhancers (Niakan et al., 2010). In addition to SOX2 and SOX17, SOX21 is also 
expressed in TSCs, and its expression has been found in a subset of TE derived extraembryonic 
cells. However, its role remains elusive, since although overexpression of SOX21 has an effect 
on TSC differentiation favoring some fates over others, Sox21 knock out animals survive the 
embryonic period with no major phenotypes (Cheung et al., 2017; Kiso et al., 2009; Moretto 
Zita et al., 2015). 
More than ten years ago, the first induced pluripotent stem cells (iPSCs) were produced by 
transducing mouse embryonic or adult fibroblast with expression constructs for Oct4, Sox2, Klf4 
and c-Myc (OSKM) (Takahashi and Yamanaka, 2006). Reprogramming of differentiated cells had 
already been done, by transferring nuclear content into oocytes (Wilmut et al., 1997) or fusing 
cells with ESCs (Cowan et al., 2005) but the possibility to do this by adding only four factors 
opened up the field of regenerative medicine. It has been shown that upon expression, OSKM 
bind target genes cooperatively to induce expression and epigenomic changes, where OSK act as 
pioneering factors binding to inactive chromatin and c-MYC mainly stabilizes OSK binding to 
make reprogramming more efficient (Soufi et al., 2012). Furthermore, in a single-cell single-
molecule study it was shown that SOX2 binding is the first event in which SOX2 searches the 
DNA for binding sites, and when found, OCT4 joins and the binding is stabilized (Chen et al., 
2014). 
1.1.2 SOX in tissue specific stem cells 
As organogenesis starts, SOX TFs become widely expressed and are involved in the 
development of most organs, either regulating stem cell identity, or as fate specification and 
differentiation inducers (Kamachi and Kondoh, 2013). Briefly, stem cell expression can be 
found in the developing nervous system where it governs stem cell maintenance (Bylund et al., 
2003; Scott et al., 2010) and glial specification (Stolt and Wegner, 2010), in neural crest 
regulating pluripotency, migration and fate choices  (Haldin and LaBonne, 2010), in skeletal 
muscle satellite cells regulating cell cycle progression (Lee et al., 2004), in chondrocytes ensuring 
proper differentiation during skeletal development (Lefebvre, 2009), in endothelial cells and 
lymphatic system (Corada et al., 2013; Hosking et al., 2009; Wat et al., 2012) and in 
mesenchymal progenitor cells important for survival (Bhattaram et al., 2010). Since SOX activity 
in some organs is of higher relevance to this thesis, the stem cell expression in these cells will be 
discussed in greater detail. 
1.1.2.1 Neural stem cells 
At the time of neural induction, just after the formation of the primitive endoderm and 
concomitant with gastrulation, SOX1 and SOX3 expression is induced in the already SOX2 
expressing epiblast, which together specifies the future CNS (Uchikawa et al., 2011). After neural 
tube formation, most neural stem cells (NSCs) express SOX1/2/3 in a redundant fashion and 
will continue to do so also in the adult (Favaro et al., 2009; Pevny and Nicolis, 2010), where they 
maintain the stem cell state and counteract the progression of neurogenesis, partly by blocking 
the activity of NOTCH signaling induced proneural proteins (Bylund et al., 2003; Holmberg et 
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al., 2008). This function is counteracted by the expression of the closely related SOX21, which 
instead promotes cell cycle exit and differentiation (Sandberg et al., 2005). 
In addition to blocking differentiation, SOX2 also acts to reduce cell cycle activity by directly 
binding to and repressing the CyclinD1 (Ccnd1) promoter, preserving stem cell characteristics 
(Hagey and Muhr, 2014). Apart from these important functions, SOX1/2/3 further provides 
neural specificity to the signal interpretation of SHH and BMP along the dorsoventral axis of the 
spinal cord. This is achieved by co-binding gene regulatory regions together with the GLI and 
SMAD effectors of these pathways to activate the expression of target genes in distinct neural 
precursor cell populations (Oosterveen et al., 2012; 2013; Peterson et al., 2012). 
Apart from binding and activating gene expression specific to NSCs, SOX2/3 also bind 
enhancers of silent genes not expressed in NSCs, but instead in differentiating neurons. While 
the binding of active genes is associated with the active histone modification H3K4me3, 
prebinding of silent genes is associated with both active (H3K4me3) and repressive (H3K27me3) 
histone modifications resulting in a poised state of the enhancers (Bergsland et al., 2011). A 
similar scenario is seen in ESCs where SOX2 prebinds genes that will later become active in 
NSCs (Lodato et al., 2013). This has led to a model where SOX prebinding promotes the 
formation of a permissive chromatin state allowing for rapid activation when the correct cellular 
context allows, and also where premature activation of these sites is inhibited by the prebinding 
itself (Bergsland et al., 2011). 
In addition to the members of the SOXB family (SOX1/2/3 and SOX21), members of the 
SOXD (SOX5/6) and SOXE (SOX8/9/10) families are also expressed in NSCs. While SOXE 
members are mostly studied for their role in glial specification and differentiation, SOXD 
members have been found to modulate this function, but also to induce cell fate specification of 
distinct neuronal subtypes in the forebrain (Batista-Brito et al., 2009; Kwan et al., 2008; Lai et 
al., 2008; Stolt and Wegner, 2010; Stolt et al., 2006). Additionally, SOX5 has also been 
implicated in cell cycle regulation during development in vertebrate NSCs (Martinez-Morales et 
al., 2010). Although, most of the SOX TFs expressed in NSCs during development remain in 
adult NSCs, their functions in these cells have been less studied, except for those of SOX2 
(Favaro et al., 2009; Ferri et al., 2004). 
1.1.2.2 Endodermal stem cells 
The endodermal organs esophagus, lung, stomach, liver, pancreas and intestine are all derived 
from an embryonic structure called the foregut. The foregut is a tube structure, developing much 
like the neural tube but in this case by the folding of the definitive endoderm (Sherwood et al., 
2009). Patterning signals from the surrounding mesoderm, including WNT, BMP and FGF, 
induce budding of the foregut, which will create the domains that eventually bud off into the 
respective organs between E9.5 and E11.5 (Jacobs et al., 2012). In the foregut, SOX2 expression 
can be found in a patterned manner, with high expression anteriorly and dorsally. The 
dorsoventral gradient of SOX2, which is opposite to that of NKX2-1, is important for trachea 
and esophagus separation, and with decreased levels of SOX2 this separation will fail (Que et al., 
2007). As the future lungs bud off, the low SOX2 levels will soon increase to become high in the 
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proximal airways (from trachea to bronchioles) and stay low in the distal airways (terminal 
bronchioles to alveolar ducts), where instead SOX9 is highly expressed. In the adult lung the 
SOX2 gradient is maintained and expression can be found in basal progenitors of the proximal 
airways, which serves important functions during regeneration after tissue damage (Que et al., 
2009).  
The stomach, similar to the trachea, expresses high levels of SOX2 that ends abruptly at the 
boundary between the stomach and the small intestine. At this junction, the expression of SOX2 
is mutually exclusive with that of CDX2, marking the intestine (Sherwood et al., 2009). The high 
SOX2 levels during early development will progressively become lower in the glandular, distal 
stomach, and this coincides with the development from the simple cuboidal epithelium into the 
stratified squamous epithelia of the forestomach and the columnar gland forming epithelia of the 
glandular stomach (McCracken and Wells, 2017). SOX2 expression will remain into adulthood 
marking basal stem cells of the forestomach and gland stem cells in the glandular stomach 
(Arnold et al., 2011). 
In the foregut and its derived organs, SOX2 expression is closely followed by that of SOX21 
(Sherwood et al., 2009). Although Sox21 deleted mice have not revealed any gross abnormalities 
in these organs, they have not been investigated in detail (Kiso et al., 2009).  
1.1.3 Adult stem cells and tissue homeostasis 
Adult resident stem cells constitute a minority of an organ and they serve to regenerate the 
multiple specialized cells that make the organ functional. Adult stem cells have been identified in 
most organs, but they differ in their abundance, proliferative and productive activity depending 
on the specific demands of the organ (Batlle and Clevers, 2017). For instance, the digestive tract 
constantly renews itself. The lifetime of a differentiated cell is between 7-10 days in mouse gastric 
epithelium, which therefore must have a very active stem cell compartment responding to this 
demand (Barker et al., 2010). This stem cell compartment express SOX2, but while deletion of 
these cells drastically affects tissue homeostasis, SOX2 expression by itself seems to be 
dispensable for stem cell function (Arnold et al., 2011; Sarkar et al., 2016).  
In contrast to the epithelial organs with rapid turnover, most cells of the adult brain are never 
replaced and cell renewal is only rarely seen and then only in specific regions (Frisén, 2016). 
These neurogenic regions include the subgranular zone in the dentate gyrus of the hippocampus 
and the subventricular zone (SVZ) lining the lateral ventricles, which in mice give rise to 
interneurons of the hippocampus and olfactory bulb respectively (Hsieh, 2012). What kind of 
cells and how many these neurogenic zones give rise to in humans still remains a controversial 
question (Ernst et al., 2014; Sorrells et al., 2018; Spalding et al., 2013; Wang et al., 2014). Stem 
cells in these niches express several SOX proteins including SOX1/2/3 (Ellis et al., 2004; Ferri 
et al., 2004), SOX8/9/10 (Scott et al., 2010), SOX5/6 and SOX21 (Kurtsdotter et al., 2017), 
but have mostly been studied in the context of SOX2. Adult ablation experiments have revealed 
the importance of SOX2 for self-renewal and survival of hippocampal stem cells (Favaro et al., 
2009), and loss of SOX2 leads to an increase in repressive histone modifications at genes that are 
normally bound by SOX2 (Amador-Arjona et al., 2015). 
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1.1.4 Cancer stem cells 
The concept of cancer stem cells (CSCs) has been a hot topic in recent years, and the 
identification of their presence in a large number of different tumor types, mostly based on 
xenograft studies, have followed in rapid succession since the days of their recognition (Batlle 
and Clevers, 2017). Their definition has evolved over the years but it is still is based on 
similarities to normal stem cells, where a limited number of dedicated cells can produce and 
sustain the tumor mass (Nguyen et al., 2012; Valent et al., 2012). However, although the name 
might imply it, CSCs should not be confused with normal stem cells as always being the cells of 
origin for cancer. The definition states nothing about in what cell the first mutation arose or 
which was the first cell to become malignant. Although mutations and epigenetic alterations 
could in fact arise in stem cells, they could also arise in progenitor cells or cells further down the 
differentiation path, which would then acquire stem cell properties (Clarke et al., 2006; Valent et 
al., 2012).  
CSC theory suggests that malignant stem cells produce transit amplifying and differentiated 
progeny that, at least in the beginning, show hierarchical resemblance to the tissue they arose in 
(Valent et al., 2012). Although, this seems to be true for many cancers, there are exceptions, and 
CSCs need not to be rare nor quiescent as was earlier suggested (Batlle and Clevers, 2017). Since 
CSCs are thought to be the main cause of relapse after treatment, therapies targeting CSCs were 
in the beginning of the field specifically thought to hold great promise as it was theorized that the 
ablation of CSCs would lead to the cessation of cancer growth. As it is becoming increasingly 
clear that the plasticity of normal stem cells seems to be more important than previously thought, 
remarkable CSC plasticity has also be demonstrated both in cell lines and primary cultures, where 
transit amplifying, or even fully differentiated cancer cells, can take on CSC features depending 
more on the niche than on cell intrinsic properties (Batlle and Clevers, 2017; Gupta et al., 2011; 
Shimokawa et al., 2017). Taken together, although successful treatment most likely will have to 
include specific targeting of CSCs, these cells can be of multiple identities within a single tumor, 
residing in several niches and be driven by different molecular programs. Consequently, as the 
CSC most likely represents a moving target, this constitutes a great challenge and will probably 
require a multi-targeting approach (Lathia et al., 2015). 
SOX expression has been characterized in CSCs from a variety of tissues including brain, lung, 
colon, skin, and more (Gangemi et al., 2009; Lundberg et al., 2016; Santini et al., 2014; Singh et 
al., 2012; Vanner et al., 2014). This expression mostly relates to SOX2 and its function as an 
oncogene in these settings, but SOX9 has also been shown to maintain self-renewal and 
tumorigenicity of CSCs (Kawai et al., 2016; Larsimont et al., 2015; Matheu et al., 2012; Santos 
et al., 2016; Sashikawa Kimura et al., 2011). In addition, many more SOX TFs have been found 
to be differentially expressed in cancer cells compared to normal tissue, where some are 
correlated with worse prognosis and others with a survival benefit. The relevance of SOX 
expression in the case of glioma and gastric cancer will be discussed in greater detail in the 
following chapter. 
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1.2 CANCER 
A beloved family member has during the writing of this thesis passed away in cancer. My dear 
aunt, who will be greatly missed by a lot of people. In passed years, I have already lost another 
aunt, an uncle and my grandfather. Two of my other aunts, and my father have been treated for 
cancer, and many more if I include the extended family and friends. There is no hereditary cancer 
in my family, this is just life as it is for most people. Cancer affects us all, and during our lifetime, 
one third of us will at some point receive a cancer diagnosis. The cancer burden is increasing in 
our society, which can be ascribed to an aging population, better screening and diagnostics, but 
also to a changed lifestyle with more cancer inducing risk factors (tobacco use, alcohol 
consumption, obesity and low intake of fruit and vegetables) (Stewart and Wild, 2014). Although 
the treatment of many cancers has seen great progress and the long term survival for all cancers 
combined has greatly improved since the 1970’s – from 35% 5-year survival in men and 48% in 
women, to just above 70% for both men and women today – some cancers have proven 
notoriously difficult to treat and therefore seen little progress, among them brain cancer and 
stomach cancer (Socialstyrelsen, 2013). 
From a historical perspective, the term cancer originates from the words karkinos and karkinoma 
coined by Hippocrates (460-360 BC), father of medicine, to describe diseases that produced mass 
(onkos). Cancer has plagued humanity, from prehistoric times to presence, but the earliest solid 
evidence for cancer comes not from humans, but from dinosaurs that lived ~70 million years 
ago. Both benign and malignant tumors have been found in fossils from the duck-billed dinosaur 
Cretaceous hadrosaur, indicating that cancer is indeed an old phenomenon (Faguet, 2015). The 
earliest human, or hominin, cancer found is an osteosacoma in a 1.7 million-year-old fossil from 
South Africa (Odes et al., 2016). Moreover, there are also descriptions of cancer found in 
Egyptian papyri written 1500-1600 BC, in which not only the cancer itself is described, but also 
surgical, pharmacological and magical treatments for the disease (Faguet, 2015).  
We can conclude that cancer has been with us as a part of human life and death from the very 
beginning, and will continue with increasing incidence to burden our society in the future. To 
answer to this ever increasing health threat, we need to continue to increase our understanding of 
its origins and mechanisms of progression, to find new treatments, and hopefully cures, to be 
able to manage this devastating disease. 
1.2.1 Prevalence 
Cancer is a major cause of death and morbidity all over the world. Although anyone can be 
afflicted, the incidence and mortality of specific cancers will vary greatly in different areas of the 
world. There is a difference in genetic predisposition to various cancers, but also in risk factors 
across the world with some cancers being associated with poverty and some with an 
industrialized life style. It is estimated that the cancer incidence will increase with more than 70% 
in the coming two decades, and much of this increase will be seen in low and middle-income 
countries. These are countries that already struggle with cancers linked to poverty such as 
infection-related cancers, and which will now see a rise in cancers associated with an 
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industrialized life style with the increase of obesity, tobacco use and high intake of alcohol and 
processed foods. (Stewart and Wild, 2014)  
In Sweden, we have seen a 40% increase in the number of newly diagnosed cases since 1970, and 
cancer is expected to continue this increase with approximately 1% per year. The most common 
cancer in Sweden is prostate cancer, which is closely followed by breast cancer and they account 
for about 30% of the cancer cases for men and women separately. The following most common 
cancers are skin cancer, colon cancer, lung cancer and malignant melanoma. The most notable 
single risk factor for cancer development is tobacco smoking, and its effect on several cancers is 
well established. In Sweden, about 15% of all cancer cases are estimated to have a link to 
smoking and this includes cancers of the lung, head and neck, bladder, kidney, stomach, liver and 
pancreas (Socialstyrelsen, 2013). 
1.2.2 Hallmarks of cancer 
Cancer is not one disease, but rather a collection of diseases that differ substantially between 
people, even within the same cancer type. Genetic alterations, phenotype and prognostics vary 
greatly, not only between people but also dynamically within tumors. Despite this, some 
fundamental properties are shared between all cancers, and they are what have come to be 
known as the hallmarks of cancer (Hanahan and Weinberg, 2000). These hallmarks are a set of 
principles that cancer cells use to thrive (Figure 1). When this idea was first proposed, six 
hallmarks were recognized as being crucial for cancer growth and they included self-sufficiency 
in growth signals, insensitivity to anti-growth signals, evading apoptosis, sustained angiogenesis, 
limitless replicative potential and tissue invasion and metastasis (Hanahan and Weinberg, 2000). 
They were later updated to also include two enabling characteristics; tumor promoting 
inflammation and genome instability and mutation, and two emerging hallmarks; deregulation of 
cellular energetics and evading immune destruction, (Hanahan and Weinberg, 2011). 
 
Figure 1. The hallmarks of cancer. Adapted from (Hanahan and Weinberg, 2011) 
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1.2.2.1 Self-sufficiency in growth signals 
While normal cell growth and proliferation are limited by the availability of growth factors, to 
ensure homeostasis and proper tissue organization, cancer cells have acquired self-sufficiency 
and are no longer depending on limiting mitogenic signals. There are several ways by which 
cancer cells can achieve this function and one is by simply producing the growth factor 
themselves, so that together with the expression of the appropriate receptor, an autocrine loop is 
established (Patsialou et al., 2009). Alternatively, cancer cells can stimulate surrounding tissue, 
the cancer stroma, or differentiated cells within the tumor to provide the limiting mitogen (Wang 
et al., 2018). Furthermore, the growth signal itself can be enhanced by overexpressing the wt 
receptor or a mutated activated version of it, which is independent of ligand binding for signal 
transduction (An et al., 2018). Additionally, growth factor independence can also be achieved by 
mutations deregulating downstream components of the pathway that will ultimately result in 
increased pathway activation independent of receptor signaling (Hanahan and Weinberg, 2011).  
1.2.2.2 Insensitivity to anti-growth signals 
The ability to sense when to stop proliferating is essential for tissues in order to prevent 
hyperplasia or genotoxic effects by DNA damage. The two most important pathways for sensing 
this are the RB cell cycle pathway and the p53 tumor suppressor pathway. While RB receives and 
conveys responses from both extracellular signals, including contact inhibition, and intracellular 
signals such as oncogene activation and hyperproliferation, p53 mainly senses intracellular 
stresses such as DNA damage. Consequently, activation of the RB pathway will lead to a halt in 
the cell cycle, and activation of the p53 pathway will lead to cell cycle arrest, transient or 
permanent (senescence), DNA repair or apoptosis depending on the strength and duration of 
the signal (Meek, 2009). With these important regulatory functions, it is not surprising to find 
some of the most frequent cancer mutations in these pathways, both as mutagenic activations or 
gene amplifications of oncogenes and as homozygous deletions or epigenetic silencing of tumor 
suppressors (Brennan et al., 2013). 
1.2.2.3 Evading cell death 
Programmed cell death (PCD), which in contrast to necrosis is a highly regulated and controlled 
process, can occur by multiple mechanisms, which are all implicated in cancer development. The 
best studied and probably most relevant of these, apoptosis, can be activated by the extrinsic or 
the intrinsic pathway, where the former is receiving extracellular death-signals and the latter is 
sensing various intracellular stresses. Signaling through either the extrinsic or the intrinsic 
pathway results in the activation of the effector Caspases; Caspase 3, Caspase 6 and Caspase 7 
and proteolytic degradation of cytosolic content (Li and Yuan, 2008; Mariño et al., 2014). The 
intrinsic program, sensing intracellular stressors such as DNA damage, oncogene activation and 
hyperproliferation, is more widely implicated cancer. It involves the permeabilization of the outer 
mitochondrial membrane (MOMP) and the release of cytochrome c, serving as a decisive event 
in determining whether a cell will commit to apoptosis or not (Fuchs and Steller, 2015). 
Cytosolic cytochrome c will promote the assembly of the apoptosome, a multiprotein complex 
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to which Caspase 9 is recruited and activated, and ultimately lead to the proteolytic cleavage and 
activation of the effector Caspases (Li and Yuan, 2008).  
The process of MOMP is regulated by the BCL-2 family of proteins, containing both anti-
apoptotic and pro-apoptotic members. In healthy cells, the anti-apoptotic BCL-2 and its close 
relatives BCL-XL, BCL-W, MCL-1, BCL-B and A1, are counteracting pro-apoptotic BAX and 
BAK of the same family. As stress signals are transmitted, (BCL2 homology domain 3) BH3-
only proteins, a third part of the family, are induced either transcriptionally, by p53 activation, or 
post-translationally. These pro-apoptotic proteins, including BIM, BID, PUMA, BAD and 
NOXA neutralize the anti-apoptotic proteins and activate BAX and BAK leading to their homo 
oligomerization in the mitochondrial membrane, MOMP and cytochrome c release (Czabotar et 
al., 2014). Other modes of PCD include necroptosis and cell death induced by autophagy, where 
necroptosis is a controlled version of necrosis often induced by the same extracellular stimuli as 
for apoptosis, but where the downstream pathway is distinct, including several members of the 
RIPK family (Shan et al., 2018). Autophagy on the other hand, is essentially a cell preserving 
mechanism by which the stressed cell is trying to recycle its resources by degrading cytoplasmic 
content in autophagosomes, thereby preventing cell death (Mariño et al., 2014). If these 
precautions are insufficient, cell death will occur, either directly induced by autophagy, or more 
commonly, by the induction of apoptosis (Mariño et al., 2014).  
Tumor cells find multiple ways to escape PCD, and apoptosis can be avoided by genetic 
aberrations at several levels. Cancer cells frequently up-regulate the anti-apoptotic BCL-2, BCL-
XL or other survival signals, or alternatively downregulate the pro-apoptotic BAX, BIM or 
PUMA. Additionally, mutations in the p53 apoptosis-inducing pathway, including TP53 itself, 
also represent a common mechanism to counteract apoptosis. Autophagy, on the other hand, 
can act either as a barrier to tumor formation or as an enhancer, depending on the cellular 
context. Therefore, the benefit for individual cancers of suppressing this pathway may differ 
depending on the underlying genetic mutations (Hanahan and Weinberg, 2011; Rosenfeldt et al., 
2013). Although PCD is actively avoided by many cancers, most cancers are not completely cell 
death resistant and some tumors are actually more sensitive to apoptosis than normal cells. 
However, while dying, tumor cells do not disappear in silence, and dying itself, not only necrosis 
but also PCD, can have a tumor promoting effect by the release of several factors acting as “eat 
me” and “find me” signals inducing angiogenesis, proliferation and immune modulation (Ichim 
and Tait, 2016).  
1.2.2.4 Sustained angiogenesis 
Just like normal cells, tumor cells depend on the delivery of oxygen and nutrients by the blood, 
and tumor neovascularization is a surprisingly early process during cancer development. Tumor 
vessels are often highly aberrant, with excessive branching, large vessels, faulty blood flow, 
microhemorrhage and leakiness. In normal tissues angiogenesis is balanced by the presence of 
pro-angiogenic and anti-angiogenic signals, a balance that is disrupted in the tumor environment, 
in part by the presence of inflammatory cells that can help to induce the angiogenic switch. 
Certain oncogenes themselves can lead to the production of pro-angiogenic factors and 
  21 
additionally, as previously discussed, signaling by apoptotic cells can lead to a pro-angiogenic 
environment (Hanahan and Weinberg, 2011). 
1.2.2.5 Limitless replicative potential 
Most cells in the body can only undergo an already defined number of cell divisions before 
permanent cell cycle arrest, also known as senescence, will definitively stop proliferation. 
Senescence is an irreversible, non-proliferative but viable and metabolically active state that is 
thought to function as a barrier to tumor development (Campisi, 2013; Hanahan and Weinberg, 
2011). Replicative senescence is induced by progressively shortened telomeres in the absence of 
telomerase. This will eventually elicit senescence via the DNA damage response (DDR) signaling 
through ATM and ATR kinases and the p53 pathway (Kuilman et al., 2010). Unsuccessful 
execution of this program will lead to the fusion of chromosome ends, and this together with 
following rounds of mitosis will give rise to genomic instability by cycles of fusion and breakage 
of chromosomes. This will, under normal circumstances, induce cell crisis and death, unless 
other genetic perturbations are present. If these genomically instable cells are able to escape 
senescence or death, they can instead vastly contribute to tumorigenesis (Campisi, 2013).  
In addition to telomere function, other signals can also contribute to senescence and thus 
prevent tumorigenesis, including DNA damage (outside the telomeres), oncogenic signaling, 
hyperproliferation and epigenetic damage. These signals are mainly transmitted by the master 
transcriptional regulators p53 and RB, where p53 activation will lead to the transcriptional 
activation of the downstream effector p21 which together with activated INK4A (also known as 
p16), an upstream regulator of RB, will halt cell cycle progression (Campisi, 2013).  
Similar to PCD, senescent cells are not silent, instead they actively signal to their environment by 
a process known as Senescence-Associated Secretory Phenotype. This is a function that has been 
found to have both beneficial and deleterious effects. Beneficial in the way that it helps to 
establish the tumor suppressing senescent growth arrest, and deleterious in the way that it can 
stimulate proliferation and angiogenesis (Campisi, 2013). Although senescent cells constitute a 
frequent find in premalignant lesions, where they can have a beneficial function for the 
neoplastic community of cells, eventually for malignant progression to occur, tumor cells need to 
acquire a mechanism to maintain sufficient telomere length to avoid senescence and apoptosis. 
This is most often achieved by the upregulation of telomerase and less frequently by an 
alternative mechanism involving recombination based telomere maintenance (Hanahan and 
Weinberg, 2011). 
1.2.2.6 Invasion and metastasis 
The capability of a tumor to disseminate from its original mass, enter the blood stream and find 
new organs to seed metastases in, is largely depending on a process known as epithelial-
mesenchymal transition (EMT) (Hanahan and Weinberg, 2011). This is a developmentally 
conserved process used in multiple stages during embryogenesis such as gastrulation, neural crest 
formation and heart development, and it involves changes in the adhesion molecule expression, 
allowing a gain in migratory and invasive behavior (Nieto et al., 2016).  
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In cancer, EMT TFs, mainly of the SNAIL, TWIST and ZEB families, are expressed and play an 
important role in all stages of tumor development, as they facilitate tumor growth, invasion, 
dissemination and metastasis, colonization and therapy resistance (Hanahan and Weinberg, 
2011; Nieto et al., 2016). Additionally, EMT TFs have also been shown to maintain stemness 
properties. During the process of EMT, which is multistep and can also be partial, cells loose 
their epithelial characteristics, as seen by the downregulation of certain markers such as E-
cadherin, Occludins and Cytokeratins. Further down the EMT process mesenchymal markers 
such as N-CADHERIN and VIMENTIN are up-regulated as the cells become highly migratory 
and invasive. EMT is not only, as the name might indicate, important for tumors of epithelial 
origin but is also a common feature of non-epithelial tumors such as glioma, melanoma, sarcoma 
and even leukemia (Nieto et al., 2016). 
1.2.2.7 Genome instability and mutations 
As an enabling characteristic, genome instability and mutability creates the functional 
heterogeneity among premalignant or malignant cells that facilitates the expansion of clones with 
beneficial traits, thus enabling tumorigenesis to occur or proceed. This can be achieved either by 
an increased sensitivity to mutagenic agents or by defective genomic maintenance, or by both. In 
addition, it can also be achieved by a broken surveillance and safety system, where cells with 
genomic damage should be neutralized, either by senescence or apoptosis, but escape and 
prevail. Consequently, cells with faulty or even oncogenic genomes are allowed to persist and the 
mutability can accelerate (Hanahan and Weinberg, 2011).  
Although any cancer typically has large number of mutations, a small number of tumors have an 
elevated mutation rate and an increased mutation burden. This hypermutation phenotype is 
often found in cancers that evolve in a mutagenic environment such as in the case of melanoma 
(UV-light) or lung cancer (tobacco smoke), but is also found in many other cancers and can 
sometimes even be treatment induced and arise after relapse. Mutations in genes important for 
DNA replication repair or DNA mismatch repair are frequently associated with a hypermutation 
phenotype (Campbell et al., 2017). 
1.2.2.8 Tumor promoting inflammation 
Cells from both the innate and adaptive immune system are attracted to the developing tumor, 
and can be found in virtually all tumors, although with varying density. Despite the fact that 
these immune cells are probably attempting to clear the lesion, they paradoxically end up 
promoting tumorigenesis. Macrophages, mast cells, neutrophils and T and B lymphocytes that 
accumulate at the tumor site have all been shown to have their part in tumor promotion, mainly 
by secreting growth factors, survival factors, pro-angiogenic factors and extracellular matrix-
modifying enzymes. This leads to sustained proliferation, decreased tumor cell death, and a 
facilitation of vessel formation, invasion and metastasis. Together with chemokines and 
cytokines that amplify the chronic inflammation, this creates a tumor thriving environment. 
Additionally, inflammatory cells release reactive oxygen species that increase the mutagenesis in 
nearby tumor cells thereby accelerating tumor progression (Hanahan and Weinberg, 2011). 
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1.2.2.9 Deregulation of cellular energetics 
Under normal conditions most cells use oxidative phosphorylation as a way to produce energy in 
the form of ATP. Glycolysis, the first part of glucose catabolism, is mainly used as the dominant 
source of ATP production in anaerobic or hypoxic conditions and has the benefit of not needing 
oxygen, but in return produces less ATP. Energy metabolism is rewired in cancer cells and a 
switch is induced, from oxidative phosphorylation to glycolysis alone, a mechanism known as the 
Warburg effect. Why tumor cells do this, even in non-hypoxic conditions, is not completely 
clear, and although this is a common phenomenon, there are still many questions to be answered 
(Liberti and Locasale, 2016). It has been speculated that this may be a way to increase the 
production and availability of nucleotides and amino acids required by the tumor cells for the 
rapid growth, by shunting partially degraded glucose into various biosynthetic pathways 
(Hanahan and Weinberg, 2011). 
1.2.2.10 Avoiding immune destruction 
In an immune competent host, the vast majority of tumorigenic cells arising are thought to be 
eliminated by immune surveillance. This process, also called cancer “immunoediting”, is said to 
have three phases: elimination, equilibrium and escape. By continuously removing immunogenic 
tumor cells, a selection for cells with reduced immunogenicity occurs, which may eventually lead 
to immune escape, enabling tumor growth (Fouad and Aanei, 2017; Hanahan and Weinberg, 
2011). Interestingly, patients with some types of cancer exhibiting heavy tumor infiltration of 
Cytotoxic T-lymphocytes (CTL) and Natural Killer cells actually have a better prognosis 
(Hanahan and Weinberg, 2011).  
1.2.3 Glioma 
1.2.3.1 Prevalence 
The most common source of tumors in the brain is metastases from cancers outside the CNS, 
which are 5-10 times more common than primary brain cancer (Weller et al., 2015). Primary 
brain cancer occurs in both children and adults, but differ significantly in frequency, location, 
tumor type and prognosis. While primary brain cancer is the second most common cancer 
diagnosis in children (30% of all pediatric cancer) only surpassed by lymphomas together with 
leukemia, it is relatively uncommon in adults, accounting for only 2.5% of the cancer diagnoses 
in Sweden and 2% worldwide (Socialstyrelsen, 2013; Stewart and Wild, 2014). However, the 
impact of brain cancer is dramatic. In children, brain cancer is the leading cause of cancer-related 
death and in adults, although being rare, malignant brain cancer results in more years of life lost 
than do any other tumor (Rouse et al., 2016).  
Glioma is the most common primary brain tumor type at all ages, but in children, embryonal 
tumors (mainly medulloblastomas) are almost as frequent. (Ostrom et al., 2017). The incidence 
rate of glioma increases with age, being the highest in the age group of 75-84 years. The reason 
for this is unknown, and although several environmental factors have been studied, the only one 
that has been recognized as causative is ionizing irradiation, where the effects of primary 
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pediatric brain cancer treatment is seen later in life, in the form of new malignancies of the brain 
(Weller et al., 2015). 
1.2.3.2 WHO Classification 
Brain cancer is diagnosed according to the World Health Organization (WHO) classification 
system that was recently updated, for the first time adding molecular parameters to the diagnosis 
criteria (Louis et al., 2016). In recent years a large number of sequencing projects have added 
significantly to our understanding of the molecular differences behind different glioma subtypes, 
including affected signaling pathways and driver mutations, which in part has led to the update. 
The classification system also includes grading for malignancy, where grade I is benign and grade 
IV the most malignant.  
Gliomas account for almost 30% of all primary adult brain tumors, and being mostly highly 
malignant they are also responsible for the majority of deaths within this group. The larger part 
of glioma is classified under the group “diffuse astrocytic or oligodendroglial tumors”, in which 
oligodendrogliomas are of grade II-III and astrocytomas of grade II-IV (Reifenberger et al., 
2017). The most malignant grade IV astrocytoma is called Glioblastoma Multiforme (GBM) and 
it is sadly also the most common, accounting for more than 50% of all glioma. GBM is incurable 
and has a 5-year survival rate of only 5.5% (Ostrom et al., 2017). The poor outcome is mainly 
due to two characteristics of this disease, the first being its infiltrative growth, making complete 
surgical resection impossible. The second is the presence of cells with a strong resistance to 
chemo and radiotherapy, causing re-growth of the tumor (Zong et al., 2015). 
1.2.3.3 Molecular Classification 
In recent years, several large-scale sequencing efforts have rapidly expanded our knowledge and 
helped to map and classify many of the primary malignancies of the brain, often better than 
standard histological classification (Brennan et al., 2013; Buczkowicz et al., 2014; Cancer 
Genome Atlas Research Network, 2008; Cancer Genome Atlas Research Network et al., 2015; 
Ceccarelli et al., 2016; Jones et al., 2013; Pajtler et al., 2015; Parker et al., 2014; Sturm et al., 
2012; Suzuki et al., 2015; Verhaak et al., 2010; Wu et al., 2014; Zhang et al., 2013). Several of 
these studies are based on material collected by The Cancer Genome Atlas (TCGA) project, 
which has collected data from more than 11,000 tumors of 33 cancers types, and which also has 
an Internet platform for easy access of all their data (Hutter and Zenklusen, 2018). Glioma and 
GBM were among the first tumors to be collected and are probably also the best-studied 
malignancies in this dataset.  
The first molecular classification of GBM was proposed by TCGA to include a Proneural, 
Neural, Classical and Mesenchymal subtypes. The characteristic genetic events were found to be 
IDH mutation, PDGFRA alteration and TP53 mutation/loss of heterozygosity for the Proneural 
class, expression of neuron markers for the Neural class, EGFR amplification, TP53 mutation 
and homozygous CDKN2A deletion for the Classical class and deletions and mutations affecting 
the NF1 and PTEN genes together with expression of mesenchymal markers for the 
Mesenchymal class (Verhaak et al., 2010). This classification has been mostly confirmed in 
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several studies, however, the Neural group has been removed, since refined RNA-seq using 
single cell analysis and pure tumor samples have revealed the tumors of this group as samples 
with a high degree of non-neoplastic brain cells (Wang et al., 2017). Furthermore, it is becoming 
increasingly clear, due to single cell analysis and multiple sampling of tumors, that several clones 
exists within each tumor and that they can often be of different molecular phenotypes (Meyer et 
al., 2015; Patel et al., 2014; Sottoriva et al., 2013; Wang et al., 2017). Additionally, the GBM 
subclasses are often not stable and almost half (45%) of tumors switch class after recurrence, 
which could be explained by differences in therapy resistance among present clones (Meyer et 
al., 2015; Wang et al., 2017). Altogether this means, that while intertumoral genetic and 
epigenetic mutation patterns are fairly stereotypical and can be easily categorized, the 
intratumoral polyclonality and heterogeneity should not be underestimated (Furnari et al., 2015). 
Extended work of glioma molecular classification has added three subclasses for lower grade 
gliomas and two subclasses for pediatric GBM (Cancer Genome Atlas Research Network et al., 
2015; Ceccarelli et al., 2016; Sturm et al., 2012). The lower grade clusters are all recognized by 
mutations in IDH, usually in IDH1, less frequently in IDH2, which lead to increased histone 
methylation and CpG island hypermethylation, a phenotype known as glioma CpG island 
methylator phenotype (G-CIMP) (Weller et al., 2015). IDH-mutant tumors can be divided into 
two clusters based on the presence of 1p/19q co-deletion (codel). IDH-mutant tumors with 
codel are most often oligodendrogliomas.  
Although stratifying patients in this way may seem rational, the molecular classification has so far 
only added limited diagnostic, prognostic and predictive value, the exception being the 
recognition of IDH-mutation and 1p/19q codel as diagnostic factors, which has been included in 
the 2016 WHO classification as biomarkers (Reifenberger et al., 2017). Therefore, although 
GBM constitutes one of the best genomically characterized cancers, the effect on clinical 
outcome is yet to come (Lathia et al., 2015). 
1.2.3.4 Glioma signaling pathways 
Despite the lack of effect on clinical outcome, the extensive molecular mapping of GBM has led 
to the establishment of the most frequently targeted molecular pathways, and genetic alterations 
in RB, TP53 and receptor tyrosine kinase (RTK) pathways are now recognized as core events in 
gliomagenesis. Somatic aberrations within these pathways have been found to be as frequent as 
79%, 85% and 90% respectively, and in as much as 74% of tumors, alterations can be found in 
all three pathways (Brennan et al., 2013). 
1.2.3.4.1 Receptor Tyrosine Kinase pathway 
RTK signaling, being the most widely affected pathway, is important for mediating cell growth, 
survival and proliferation through several downstream signaling cascades, most notably through 
the PI3K/AKT and RAS/MAPK/ERK intracellular pathways (Figure 2) (Pearson and Regad, 
2017). In normal cells, growth factors will bind to RTKs and induce their dimerization and 
autophosphorylation, which in turn will elicit downstream intracellular responses. Upon receptor 
activation, PI3K will translocate to the plasma membrane and induce the production of the 
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signaling molecule phosphatidylinositol 3,4,5-triphosphate (PIP3) from phosphatidylinositol 
biphosphate (PIP2), a production that is inhibited by tumor suppressor PTEN. PIP3 production 
will lead to the recruitment of AKT to the plasma membrane and its phosphorylation and 
activation by PDPK1 (Vivanco and Sawyers, 2002). AKT itself is a serine/threonine protein 
kinase that phosphorylates multiple targets within the cell, including GSK3α and GSK3ß, 
MDM2, FOXO TFs, p21 (CDKN1A) and p27 (CDKN1B) to increase survival and induce 
proliferation (Downward, 2004; O'Donnell et al., 2018).  
Figure 2. RTK signaling pathway. Oncogenes (yellow) and tumor suppressors (green) frequently 
targeted in GBM. Adapted from (Brennan et al., 2013) and (Tanaka et al., 2013). 
Additionally, RTK signaling will also result in the activation of RAS, which will, in addition to 
stabilizing PI3K, also lead to its own interaction with RAF, promoting dimerization and 
activation (McKay and Morrison, 2007; Samatar and Poulikakos, 2014). Activated RAF further 
phosphorylates the kinase MEK, which in turn phosphorylates and activates the kinase ERK. 
ERK phosphorylates multiple targets including transcription factors and will end up activating 
cellular programs promoting cell cycle progression, differentiation, survival and cell growth 
(Samatar and Poulikakos, 2014). Interestingly, despite the fact that all signaling from RAF and 
MEK is conveyed by ERK, which it is found activated in more than 85% of all cancers, no ERK 
mutations have been reported so far and all oncogenic mutations are found higher up in the 
signaling cascade (Maik-Rachline and Seger, 2016).  
Four RTKs; EGFR, PDGFRA, FGFR and MET, are commonly targeted by either mutations or 
amplifications and among them, EGFR by far most frequently (57%) (Brennan et al., 2013). 
Mutations/amplifications of different RTKs co-occur in a smaller number of tumors, most 
commonly EGFR and PDGFR. The most frequent EGFR mutation is the aberrant junction 
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between exons 1-8 which results in an oncogenic receptor, EGFRvIII, which is constitutively 
active due to the lack of the extracellular ligand binding domain (An et al., 2018). Amplification 
of the wt EGFR gene is also a common event, frequently co-occurring with at least one (71%) or 
two or more (30%) other aberrant variants of EGFR (Francis et al., 2014). The co-occurrence 
can either be within the same cell or in different subclones of the same GBM tumor adding to 
tumor heterogeneity. Moreover, downstream of RTK, mutations, deletions and amplifications 
are found at multiple levels, some co-occurring with each other, others being mutually exclusive, 
but collectively resulting in the activation of pathway output. Of special importance is two 
downstream pathway inhibitors that are often lost or mutated in GBM, that is NF1 
(mutation/deletion in 10%) of the RAS/MEK/ERK pathway and PTEN (41% 
mutation/deletion) of the PI3K/AKT pathway (Brennan et al., 2013).  
1.2.3.4.2 p53 Tumor suppressor pathway 
p53 is probably the most extensively studied tumor suppressor, partly because its gene, TP53 
(Trp53 in mice), is the most frequently mutated gene in cancer. Its important tumor suppressor 
function is demonstrated not only by the fact that it is mutated in 50% of all cancer, but also by 
the increased cancer susceptibility of individuals with Li-Fraumeni syndrome, inheriting a mutant 
TP53 allele, and also by the predisposition of Trp53 null mice to spontaneous tumor 
development (Bieging et al., 2014). p53 protects the cells from transformation by inducing, 
transient cell cycle arrest, DNA repair, permanent cell cycle arrest (senescence) and apoptosis in 
response to a wide range of cellular stresses, including DNA damage, hyperproliferative signals 
(such as oncogenic stress), hypoxia, oxidative stress, ribonucleotide depletion and nutrient 
starvation (Figure 3) (Bieging et al., 2014). In unstressed cells, the levels of p53 are kept low due 
to high p53 instability and turnover mediated by the binding of the MDM2 ubiquitin E3-ligase 
which leads to the constant break down of p53 protein by the proteasome (Kruse and Gu, 
2009). Together with MDM2, the structurally related MDM4 also regulates p53 activity, but with 
a different non-redundant mechanism. Binding of MDM4 to p53 does not lead to its 
degradation, rather to its stabilization, but since MDM4 is binding to the activation domain of 
p53, it efficiently inhibits p53-induced transcription and therefor function. Furthermore, MDM4 
can also bind to MDM2 and stabilize it, thus enhancing its function (Kruse and Gu, 2009).  
In keeping with being “the guardian of the genome” and the “cellular gatekeeper” p53 receives 
stress signals from multiple sources in the cell to coordinate the appropriate response, which 
depends on the intensity and duration of the specific stressor but also on the cell type and 
genetic background (Meek, 2009). A crucial step in the activation of p53, regardless of the 
stimulus, is its stabilization by phosphorylations and acetylations that will release it from its 
inhibitors MDM2 and MDM4 and inhibit degradation (Kruse and Gu, 2009). In the case of 
DNA damage, ATM is activated by double stranded breaks while ATR is triggered by single 
stranded breaks and replicative stress, leading to downstream activation of CHK2 or CHK1 
respectively. CHK1/2 together with ATM/ATR phosphorylates MDM2/4 and p53 ultimately 
leading to p53 accumulation and pathway activation (Meek, 2009).  
Alternatively, p53 can also be activated by ARF, sensing oncogene activation and 
hyperproliferation. ARF, which is also known as p14 (p19 in mice), is transcribed from the 
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CDKN2A locus that also produces another tumor suppressor INK4A (also known as p16), 
important for the regulation of cell cycle progression by the RB pathway (Sherr, 2006). Aberrant 
and sustained levels of mitotic signals will induce the transcription of ARF, which is normally 
expressed at undetectable levels, and ARF will phosphorylate and inhibit the function of MDM2 
(Sherr, 2006). p53 tumor suppressor activity depends mostly on its function as a TF, binding to 
sequence specific motifs as a tetramer most frequently activating target gene transcription. 
Among the many targets are p21 (CDKN1A) and GADD45A, whose activity will result in cell 
cycle arrest, senescence or DNA repair, the apoptosis inducers BAX, FAS, NOXA and PUMA, 
and the DNA repair gene MGMT. In addition, p53 also regulates the expression of genes 
important for autophagy, metabolism control, tumor environment crosstalk, invasion and 
metastasis and stem cell regulation (Bieging et al., 2014).  
Figure 3. p53 tumor suppressor pathway. Oncogenes (yellow) and tumor suppressors (green) 
frequently targeted in GBM. Adapted from (Brennan et al., 2013) and (Tanaka et al., 2013). 
Furthermore, while wt p53 is critical for tumor suppression, some p53 mutants are actually 
oncogenic and accumulate in tumor cells, adding an other layer of complexity to p53 and its 
function in tumor biology (Soussi and Wiman, 2015). In fact, it was actually as an oncoprotein 
p53 was first discovered and got its name TP53 – Tumor Protein 53 (Muller and Vousden, 
2014). The oncogenic function of mutant p53 is also reflected by the fact that although TP53 can 
be found homozygously deleted in cancer, missense mutations are far more frequent, and 
consistently, patients with germline missense mutations have a much earlier onset of tumor 
development than patients with mutations that result in loss of p53 protein (Muller and 
Vousden, 2014). Mutations can been found in all domains of TP53, emphasizing the importance 
of this gene, although most frequent is the targeting of the DNA binding domain where virtually 
all codons have been found mutated. Six, “hotspot” mutations are found in high frequency in all 
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cancers and their neomorphic, or gain of function, features have been studied extensively and 
include enhanced tumorigenesis, metastasis, resistance to therapy and genomic instability (Muller 
and Vousden, 2014; Soussi and Wiman, 2015).  
In the case of GBM, TP53 is mutated or deleted in 28% of tumors, but together with aberrations 
in MDM2 and MDM4 genes (15%) and the deletion of CDKN2A locus (58%), the pathway is 
de-regulated in 86% of all GBM (Brennan et al., 2013).  
1.2.3.4.3 RB Cell cycle regulation 
The third process heavily affected in GBM is the cell cycle, more specifically the RB pathway of 
cell cycle control (Brennan et al., 2013; Cancer Genome Atlas Research Network, 2008). In 
non-neoplastic cells, the cell cycle progression is tightly regulated by RB binding to the E2F 
family of transcription factors repressing their transcriptional activation of genes important for S-
phase and mitosis. In order to initiate and progress through the cell cycle, RB needs to be 
phosphorylated by Cyclin dependent kinases (CDK) in order to release its repression and let go 
of E2F. CDKs themselves are only active when binding to Cyclins, and different combinations 
of Cyclin/CDK complexes are responsible for initiating and maintaining RB phosphorylation 
throughout the cell cycle. CyclinD proteins are crucial for initiating the cell cycle in the early G1 
phase and their synthesis and assembly with their partners CDK4 or CDK6 are dependent on 
mitotic signals. Thereafter, the CyclinE/CDK2 complex maintains the RB repression during the 
remainder of G1, and continuously, CyclinA together with CDK2 or CDK1 take the cell through 
S-phase and G2 phase, while the CyclinB/CDK1 complex is needed for mitosis (Giacinti and 
Giordano, 2006). Under normal circumstances, as RB gets hyperphosphorylated it will stay 
inactivated until phosphatases will relieve it of its inhibitory phosphorylations at the end of 
mitosis, although there are ways for the cell to stop the cell cycle in an active phase. Members of 
the INK4 and CIP/KIP families of CDK inhibitors can bind and destabilize Cyclin/CDK 
complexes thus promoting the reactivation of RB function (Besson et al., 2008). One of the 
most important CDK inhibitors in the context of tumor suppression is INK4A, transcribed 
from the CDKN2A locus as previously described. Diverse signals such as DNA damage or 
oncogene activation will increase the normally undetectable levels of INK4A in the cell, which 
will lead to the binding of CDK4/6 and the displacement of D type Cyclins. This in turn will 
result in the release of other CDK inhibitors; p21 (CDKN1A) and p27 (CDKN1B) of the 
CIP/KIP family, that are normally binding to and stabilizing this complex, and they will further 
inhibit the activity of CDK2 complexes (Knudsen and Knudsen, 2008). In addition, together 
with INK4A the other family members INK4B (p15 from the CDKN2B gene), INK4C (p18 
from the CDKN2C gene), INK4D (p19 from the CDKN2D gene) will also bind and repress 
CDK4/6, while and p57 (CDKN1C) of the CIP/KIP family will contribute to the regulation of 
Cyclin/CDK complexes throughout the cell cycle.  
In GBM tumors, mutations or deletions of RB itself, as well as activating mutations or 
amplifications of CDKs or Cyclins are common, but the far most frequent pathway alterations 
are achieved by homozygous deletion of the CDKN2A locus or CDKN2B locus and less 
frequently the CDKN2C locus (Figure 4) (Brennan et al., 2013).  
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Figure 4. RB cell cycle regulation pathway. Oncogenes (yellow) and tumor suppressors (green) 
frequently targeted in GBM. Adapted from (Brennan et al., 2013) and (Tanaka et al., 2013). 
1.2.3.5 Cell of Origin 
As tumorigenesis begins long before the detection and diagnosis of the cancer, and multiple 
mutations and genetic alterations leading to functional and morphological changes are added 
during this process, it is inherently difficult to pinpoint the cell of origin. In theory, any cell of the 
tissue hierarchy with proliferative potential could acquire genetic changes that induce self-renewal 
and therefore could serve as the cell of origin (Visvader, 2011). Several mouse models have tried 
to define the cell of origin of glioma and GBM and together they point to several possible 
sources. Although NSCs, transit amplifying cells, oligodendrocyte progenitor cells (OPCs), 
differentiated astrocytes and even neurons have all been demonstrated to be susceptible to 
transformation, the case for NSCs and OPCs is perhaps the strongest.  
NSCs expressing NESTIN can give rise to high-grade glioma when forced to express oncogenes 
Akt and Kras or when different combinations of the tumor suppressors Trp53, Nf1 and Pten are 
deleted (Alcantara Llaguno et al., 2009; Holland et al., 2000). Consistently, using the NSC and 
astrocyte specific human glial fibrillary acidic protein (GFAP) promoter to guide tumor 
suppressor deletion, NSCs but not mature astrocytes can be induced to form tumors (Jacques et 
al., 2010; Kwon et al., 2008; Wang et al., 2009). Interestingly, although AKT and KRAS 
overexpression was not sufficient to induce gliomagenesis in GFAP expressing astrocytes 
(Holland et al., 2000), the activation of these oncogenes on a Ink4a/Arf -/- background could 
induce tumor growth in GFAP expressing cells (Uhrbom et al., 2002). Other studies have also 
confirmed the ability of differentiated astrocytes to induce tumor growth, but what most of them 
have in common and what distinguish them from studies which did not find this ability is that 
they use the expression of activated oncogenes rather than or in combination with tumor 
suppressor deletion (Bachoo et al., 2002; Friedmann-Morvinski et al., 2012; Marumoto et al., 
2009; Uhrbom et al., 2002) or induce neonatal rather than adult astrocytes (Bachoo et al., 2002; 
Uhrbom et al., 2002). Another study, using inducible hGFAP-CreER to induce the loss of tumor 
suppressors Pten/Trp53/Rb in 50% of adult astrocytes and 1% of adult NSCs, found that despite 
the fact that most targeted cells were differentiated astrocytes, most tumors (78%) arose in areas 
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close to the neurogenic niches containing NSCs (Chow et al., 2011). In summary, although both 
NSCs and astrocytes may undergo transformation, NSCs are probably much more susceptible 
and might require a lower threshold of oncogenic events to induce gliomagenesis.  
Representing the majority of the dividing cells in the adult human brain, OPCs, in addition to 
NSCs, constitute another likely source of glioma (Geha et al., 2010). In support of this, high 
grade oligodendrogliomas are generated when an activated allele of EGFR (v-erbB) is expressed 
under the control of the human S100ß promoter in combination with Trp53 deletion (Persson et 
al., 2010). Although S100ß is found expressed in mature astrocytes, ependymal cells and some 
neurons in addition to OPCs, the authors found that the glioma cells arising are similar to 
immortalized OPCs in their molecular expression profile and phenotype. Furthermore, the 
authors could successfully link the localization of human oligodendrogliomas in the brain to 
white matter regions, rather than the lateral ventricles, as was more common for astrocytomas, 
thus suggesting a white matter progenitor cell of origin for oligodendroglioma (Persson et al., 
2010). Consistently, another study reported similar results using lineage tracing with the Mosaic 
Analysis with Double Markers system in a mouse model where Trp53 and Nf1 were deleted in 
cells expressing hGFAP or NESTIN. Interestingly, only OPCs were found to aberrantly 
proliferate in pre-malignant animals, supporting the notion that even though the oncogenic 
mutations occur in NSCs, it is a progenitor cell that is the cell of origin of the tumor. 
Additionally, the results were confirmed by directly introducing the mutations in OPCs using 
OPC specific NG2 to drive CRE expression. Furthermore, white matter cells stereotactiacally 
transduced with a viral vector expressing PDGF and CRE causing deletion of Trp53 and Pten in a 
small subset of cells could faithfully induce GBM like tumors. Hyperproliferating transduced 
cells expressed OLIG2, again emphasizing the importance of this lineage in glioma development 
(Lei et al., 2011). Taken together it is clear that OPCs can serve as a cell of origin in malignant 
glioma and that they are susceptible to transformation by several different mutations commonly 
associated with human glioma.  
Finally, it seems comprehensive that both the transformed cell type and the underlying 
oncogenic mutations could reflect disease properties, or alternatively that the transforming 
mutations could confer selectivity targeting cells of differential susceptibility. Indeed, NSCs from 
different parts of the CNS have been shown to initiate growth of different types of tumors when 
transformed with the same mutant MYC (Swartling et al., 2012). Conversely, in some systems 
the oncogenic mutations have been found to be superior to the targeted cell type in generating 
astrocytoma versus oligodendroglioma (Lindberg et al., 2014). This again emphasizes the 
complexity of the answer to the question of cell of origin, and it is reflected by the notion that 
glioma probably constitutes a collection of diseases and therefor may have multiple origins 
(Zong et al., 2015). Although we have begun to understand the different origins of glioma in 
mouse models we are in need of translation into the human scenario, since progenitor cell types 
differ between our species.  
1.2.3.6 SOX and Glioma 
Being developmental regulators, and developmental programs being widely used by cancers to 
induce malignancy (Suvà et al., 2013), SOX TFs have been implicated in many cancers, not at 
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least glioma and GBM. As SOX2 is a key regulator of stemness both in ESCs and stem cells of a 
wide variety of adult organs, it is not surprising to find SOX2 up-regulated in a large panel of 
cancers (Sarkar and Hochedlinger, 2013). In the case of glioma, SOX2 has been linked to 
malignancy, therapy resistance, recurrence and core transcriptional regulation of glioma CSCs 
(GSC) (Favaro et al., 2014; Garros-Regulez et al., 2016; Holmberg et al., 2011; Jeon et al., 2011; 
Singh et al., 2017; Suvà et al., 2014). SOX2 has been found to be highly expressed in glioma 
tissue, with increased expression in more malignant samples (Holmberg et al., 2011; Ma et al., 
2008), and high expression has also been correlated with aggressiveness and poor outcome (Ben-
Porath et al., 2008). The development of cancer share many mechanistic features with 
reprogramming, and developmental programs are often activated de novo to induce unlimited 
self-renewal (Suvà et al., 2013). In line with this, the expression of SOX2 often coincides with 
other ESC TFs, such as OCT4, NANOG and KLF4 in high grade glioma, and the expression of 
a ESC gene target profile is correlated with increased grade and poor outcome (Ben-Porath et 
al., 2008; Holmberg et al., 2011). Consistent with its elevated expression in high grade glioma, 
genetically amplified SOX2 has been found in GBM cell lines and primary tumors, and promoter 
CpG island hypomethylation is seen in the majority of GBM (Alonso et al., 2011; Annovazzi et 
al., 2011). Furthermore, the well recognized characteristics of GSC, self-renewal and in vivo 
tumor formation (Singh et al., 2004), have in several studies been found to depend on the 
expression of SOX2 (Alonso et al., 2011; Bulstrode et al., 2017; Gangemi et al., 2009; Ikushima 
et al., 2009). This seems not only to be the case for human GBM cells but is also seen in a mouse 
model of high grade oligodendroglioma where the deletion of SOX2 significantly reduced the 
tumor growth and increased survival (Favaro et al., 2014). Additionally, SOX2 expression 
correlates with the proposed GSC marker CD133 (Bao et al., 2006; Ikushima et al., 2009) and is 
part of a core regulatory program that keeps GSC properties, even in the absence of upstream 
oncogenic signaling (Singh et al., 2017). This function is further supported by the 
reprogramming of terminally differentiated GBM cells, which requires SOX2 together with 
OLIG2, SALL2 and POU3F2 (Suvà et al., 2014). An additional genomic feature important for 
the gene regulatory network downstream of SOX is the overrepresentation of SOX binding 
motifs in open chromatin in GBM cells, as well as in enhancers with reduced CpG island 
methylation in IDH mutant non-codel glioma (Bulstrode et al., 2017; Ceccarelli et al., 2016). 
Although there are two more members in the SOXB1 group, with extensively overlapping 
expression and function in NSC (Bylund et al., 2003; Uchikawa et al., 2011), the focus on SOX2 
has been dominating the field, and there are few reports of SOX1 and SOX3 and their relevance 
for glioma. The expression of SOX1 and SOX3 is overlapping with that of SOX2 in glioma, 
especially in GBM, and SOX1 has been suggested to serve a similar function to that of SOX2 in 
glioma cells in that its downregulation cause decreased self-renewal capacity and differentiation 
(Garcia et al., 2017; Holmberg et al., 2011). Similarly, SOX21 has also been detected to overlap 
in its expression with SOX2 in glioma tissues and cell lines, but in contrast to SOX2 and SOX1, 
SOX21 overexpression decrease proliferation and instead induce apoptosis, possibly through the 
binding to and downregulation of SOX2 protein (Caglayan et al., 2013; Ferletta et al., 2011).  
Being expressed both in mature and immature cells of the glial lineage, SOXE expression have 
been systematically investigated in glioma. As a consequence of the histopathological diagnosis 
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criteria where the tumors are defined as astrocytic or oligodendroglial, several groups have tried 
to evaluate the in normal tissue oligodendroglial-specific expression of SOX10 as a marker to 
distinguish the subtypes. This has proven impossible, since SOX10 is expressed, in varying levels 
across all glioma pathologies, also in varying degrees together with the other SOXE members 
SOX8 and SOX9 (Bannykh et al., 2006; Ferletta et al., 2007; Schlierf et al., 2007). The 
expression of SOX9 overlaps to a great extent with that of SOX2 and high expression has been 
linked to increased malignancy and poor prognosis (Garros-Regulez et al., 2016; Wang et al., 
2012). Functionally, SOX9 is important for self-renewal and survival, which has been 
demonstrated by knock-down experiments in several glioma cell lines, and mechanistically, 
SOX9 is acting downstream of SOX2, being transcriptionally regulated by mTOR and 
translationally by cGKII (Garros-Regulez et al., 2016; Hiraoka et al., 2015; Swartling et al., 
2009).  
Upstream of SOX2, TGFß stimulation has been found to induce the expression of SOX4, which 
in turn binds one of the SOX2 enhancers in a complex with OCT4, inducing SOX2 expression. 
During embryonic development OCT4 normally partners with SOX2 itself to maintain its own 
expression, a feedback loop that seems disrupted in glioma (Ikushima et al., 2009; 2011). 
Furthermore, SOX4 expression is increased in glioma compared to normal brain tissue, as is 
SOX11 of the same group, but while SOX4 is linked to poor survival, high levels of SOX11 
provides a beneficial prognosis (Korkolopoulou et al., 2013; Li et al., 2015). While being 
expressed in glioma, SOX11 is downregulated with disease progression and GSCs often lose 
their expression in culture (Hide et al., 2009). Consistently, overexpressing SOX11 in mouse or 
human GSCs decreases tumorigenicity as differentiation increases, whereas knock-down 
enhances tumorigenicity, as measured by orthotopical transplantation experiments in vivo (Hide 
et al., 2009).  
In line with a beneficial role of some of the SOX TFs, SOX17, a well-established WNT 
antagonist normally expressed in OPCs as they exit cell cycle during development (Sohn et al., 
2006), has been investigated in oligodendroglioma and also been found to confer better 
prognosis, especially in case of 1p/19q codel (Li et al., 2014). Overexpression of SOX17 in 
human oligodendroglioma cell lines, reduces proliferation and induces differentiation, through 
the upregulation of WNT antagonists and the decrease of ß-catenin (Chen et al., 2013). This 
antagonistic effect on WNT signaling and tumorigenicity has also been seen after the 
overexpression of SOX7 in glioma cell lines, and glioma patients with high grade disease are 
more likely to have low levels of SOX7 expression (Zhao et al., 2016). 
As SOXE TFs are necessary for glial specification and differentiation, members of the SoxD 
family have been found to modulate this function to time the expression of terminal 
differentiation markers (Stolt and Wegner, 2010; Stolt et al., 2006). All SOXD members are 
expressed in glioma but whether they show increased or decreased expression compared to 
normal brain tissue remains unclear (Schlierf et al., 2007; Ueda et al., 2004; 2007). Interestingly, 
a single nucleotide polymorphism (SNP) in the SOX5 gene has been correlated with an increased 
risk for primary brain tumors (Liu et al., 2012). Moreover, in a mouse model of 
oligodendroglioma, increased expression of SOX5 suppressed PDGFB-induced tumor 
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formation through the reduction of activated AKT and increased levels of p27, leading to the 
induction of senescence (Tchougounova et al., 2009). Furthermore, autoantibodies against 
SOX5 and SOX6 have been detected in the serum of glioma patients, correlating with prolonged 
survival (Schlierf et al., 2007; Ueda et al., 2004; 2007). Since SOX proteins are TFs expressed in 
the nuclei of cells, they have been considered undruggable targets. However, since 
immunotherapy for glioma has seen cautious progress it is interesting to note that successful 
DNA vaccination against SOX6 have shown both protective and therapeutic anti-tumor 
response in mice with glioma, together with an induction of CTLs specific against SOX6-
expressing glioma (Reifenberger et al., 2017; Ueda et al., 2008; Weller et al., 2017). The same 
authors have further shown that in vitro stimulation of peripheral blood mononuclear cells 
derived from healthy donors and glioma patients could induce the emergence of SOX6 specific 
CTLs, which were able to lyse several human glioma cell lines (Ueda et al., 2010). This has also 
been demonstrated for SOX11 derived epitopes that have been able to produce CTLs that can 
lyse glioma cell lines, suggesting the plausibility immunotherapy against SOX proteins in the case 
of glioma (Schmitz et al., 2007). 
1.2.4 Gastric Cancer 
1.2.4.1 Prevalence 
Stomach cancer, or gastric cancer as it is also called, is the fifth most common cancer worldwide. 
It accounts for 7% of all cancer cases, but for 9% of all cancer deaths, making it the third most 
common cancer related cause of death. Gastric cancer is not evenly distributed worldwide, rather 
there is a 10-fold difference in the incidence rates, with the highest rates found in Japan, China 
and East and Central Asia where almost 75% of all the gastric cancer cases are found. Medium 
incidence rates are found in South America while the lowest rates are found in North America, 
northern Europe and Africa (Stewart and Wild, 2014). In Sweden, gastric cancer constitutes 
between 1.2-1.7% of all cancers cases, with the higher incidence rate in men. The incidence rate 
of gastric cancer has changed tremendously over the past decades both world wide and in 
Sweden, and it has moved down from being the primary cause of cancer related death globally in 
1930, and in Sweden from being the second most common cancer in 1960 to not even be on the 
top ten list of the most common cancers today (Hayakawa et al., 2016; Socialstyrelsen, 
2013)(www.cancerfonden.se). This significant change is mainly due to improved living standards 
including sanitation, hygiene, water supply, and advances in food preservation (Balakrishnan et 
al., 2017; Wadhwa et al., 2013). However, gastric cancer is often diagnosed in advanced stages 
when the prognosis is poor, and the survival rates have not seen the same great improvement 
over the years and is still only just above 20% (5-year survival) in Sweden (Socialstyrelsen, 2013). 
This has led to screening programs in high incidence countries such as Japan, which has helped 
to bring down the death rates, and will probably continue to do so (Balakrishnan et al., 2017; 
Wadhwa et al., 2013). 
1.2.4.2 The gastric epithelium and the development of Gastric Cancer 
The human stomach is lined on the inside by a simple columnar epithelium, and is divided into 
three anatomical regions: the most proximal cardia, the corpus and the distal antrum (Choi et al., 
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2014). Rodents have instead of the cardia a large proximal compartment called the forestomach 
that instead of columnar epithelia consists of a stratified squamous epithelia continuous with the 
esophagus (Kim and Shivdasani, 2016). The gastric units of the corpus and antrum differ 
somewhat in the frequency and composition of the main cell types (Figure 5). In a typical corpus 
unit one can find pit cells located at the top of the gastric unit producing mucous and turning 
over every 3 days, zymogenic chief cells located at the bottom of the gland producing digestive 
enzymes such as pepsinogen and turning over every few months, acid-producing parietal cells 
along the length of the gland and endocrine cells secreting hormones regulating responses to 
food and starvation. Apart from almost not having any parietal cells, the antral unit instead has 
specialized cells at the gland base secreting protective acidic mucins (Kim and Shivdasani, 2016).  
Figure 5. Gastric units of corpus and antrum. 
Most stomach cancers (95%) are gastric adenocarcinomas, arising from malignant transformation 
of the gastric epithelium. Other, much less common, are lymphomas and mesenchymal gastric 
tumors (Balakrishnan et al., 2017). Most cases are sporadic, however while about 10% seem to 
be hereditary, only 1-3% of gastric cancer is caused by hereditary syndromes with known 
mutated genes (Stewart and Wild, 2014). The single biggest risk factor for gastric cancer 
development is Helicobacter pylori infection. It has been estimated to account for 89-95% of all the 
gastric cancer cases and it is considered to be a Group 1 carcinogen by the International Agency 
for Research on Cancer (Balakrishnan et al., 2017; Stewart and Wild, 2014).  
Cancer development initiated by H pylori infection passes several histopathological stages 
including chronic gastritis, atrophic gastritis, intestinal metaplasia and dysplasia before cancer is 
established (Correa, 1992). Although this does not have to be the case for all gastric cancer 
arising, and it is probably more relevant for the development of the intestinal type tumors, this 
points to the importance of inflammation in disease development (Hayakawa et al., 2017). 
Inflammation caused by H pylori infection induces aberrant DNA methylation patterns, where 
clones with beneficial phenotypes can expand and a “cancerized field” is created where the level 
of methylation correlates with cancer risk (Hattori and Ushijima, 2016; Ushijima and Hattori, 
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2012). Furthermore, aberrant methylation is not only found in pre-malignant lesions and 
metaplasia, but also in adjacent normal gastric tissue from patients with gastric cancer 
(Padmanabhan et al., 2017). This, together with the fact that some gastric cancers have a 
relatively low mutational burden and that many tumor suppressor genes such as CDKN2A, 
CDH1, MLH1 and RUNX3 are more frequently inactivated by aberrant DNA methylation than 
mutation, emphasizes methylation as a driving event in gastric tumorigenesis (Hayakawa et al., 
2017; Ushijima and Hattori, 2012).  
A subset of gastric cancers are associated with Epstein-Barr virus (EBV) infection, which also 
causes increased DNA methylation although with a different mechanism (Ushijima and Hattori, 
2012). Apart from inducing hypermethylation, H pylori also interacts with and affects stem cells 
of the stomach directly. Studies in mice have revealed that soon after infection microcolonies can 
be detected deep in the gastric glands where they induce increased proliferation of stem cells 
specifically, resulting in hyperplasia in association with chronic inflammation (Sigal et al., 2015). 
Although H. Pylori infection is deemed to be necessary, it is not sufficient to cause gastric cancer, 
and other factors modulate the risk. Diet is the most important of these factors and high intake 
of salt-preserved and/or smoked foods and pickled vegetables and low intake of fresh fruit 
vegetables increase the risk (Stewart and Wild, 2014). Smoking and high alcohol consumption 
are two other well known risk factors (Wadhwa et al., 2013). 
1.2.4.3 Molecular Classification 
Our molecular understanding of gastric cancer has been limited compared to that of other 
cancers of similar impact, and this has mainly been due to the lack of knowledge of germ line 
mutations and tumor drivers for this disease (Wadhwa et al., 2013). Recent whole genome 
sequencing efforts have tried to confront this, and progress is now seen in this area (Cancer 
Genome Atlas Research Network, 2014; Cristescu et al., 2015). Based on histology, gastric 
adenocarcinoma is divided into two subtypes, intestinal and diffuse, according to the Lauren 
classification (Laurén, 1965). This classification, or an alternative system introduced by WHO, 
which is also based on histology, provides limited diagnostic or prognostic value to this 
heterologous disease. In a quest to change this, two larger studies, including Next Generation 
Sequencing efforts, have analyzed large sets of tumors and classified them according to 
molecular profiles rather than histology (Katona and Rustgi, 2017).  
The first project, by TCGA, has identified four subtypes of gastric adenocarcinoma, based on 
comprehensive molecular evaluation of RNA, DNA and microRNA whole genome data (Cancer 
Genome Atlas Research Network, 2014). The four subgroups are EBV positive tumors, tumors 
with high Micro-Satellite Instability (MSI), Genomically Stable (GS) tumors and tumors with 
Chromosomal Instability (CIN). EBV positive tumors constitutes the smallest group and they 
are further characterized by frequent PIK3CA mutations and CIMP leading to CDKN2A 
silencing, but rarely to the silencing of the DNA mismatch repair gene MHL1. The MSI subtype 
also exhibits hypermethylation, but in contrast to EBV tumors this also includes the MHL1 
promoter, leading to increased mutation rates and a specific spectrum of mutations. The CIN 
subgroup has extensive Somatic Copy Number Alterations as apposed to the GS subgroup. The 
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CIN subgroup displays an over-representation of intestinal type histology tumors and frequent 
TP53 mutation and RTK pathway activation, whereas the GS subgroup has an 
overrepresentation of diffuse histology tumors with frequent CDH1 mutations.  
In a parallel project, lead by the Asian Cancer Research Group consortium (ACRG), expression, 
SNP and genome wide Copy Number Variation microarray data also led to the similar 
classification of four subgroups; MSI, Micro-Satellite Stable (MSS)/EMT, MSS/TP53+ with 
intact p53 activity and MSS/TP53- with loss of p53 function. Although the MSI group in the 
TCGA and the ACRG classification are relatively similar, the other subgroups while overlapping 
are different enough not to be considered equivalent (Cristescu et al., 2015). Both classification 
systems have relevant clinical association with the different subtypes, but only the groups 
proposed by the ACRG show significant survival differences between them (Cristescu et al., 
2015). 
1.2.4.4 Gastric Cancer Signaling Pathways 
Although the recent sequencing efforts have emphasized the roles of tumor suppressors TP53 
and CDH1 driver mutations in gastric cancer, it has not lead to the characterization of any 
dominant pathway heavily mutated as in the case of glioma (Cancer Genome Atlas Research 
Network, 2008; Katona and Rustgi, 2017). Instead, many pathways can be found altered with 
lower frequency, again underscoring the heterogeneous nature of this disease. Contributing to 
the genomic landscape of gastric cancer are pathways governing genome integrity, cell adhesion, 
cell motility and cytoskeleton, RTK, WNT signaling and chromatin remodeling (Katona and 
Rustgi, 2017).  
Important for genome integrity, the TP53 gene is mutated in 30-50% of all gastric cancer, and 
therefor the most common mutation. The CDH1 gene, coding for the epithelial adhesion 
molecule E-cadherin, suppress tumorigenesis by maintaining tissue organization (van Roy, 2014), 
and low levels are strongly associated with diffuse type gastric cancer. It is one of the few genes 
for which germ line mutations are linked to hereditary gastric cancer (More et al., 2007). RHOA 
functions in cell cycle motility cytoskeleton remodeling and cell proliferation and is together with 
MACF1 significantly mutated in gastric cancer. The most frequent mutations in the RTK 
pathway are in the PIK3CA gene encoding a regulatory subunit of PI3K. These mutations 
together with KRAS mutations, and much less frequent EGFR and HER2 alterations, actively 
enhance RTK signaling. WNT pathway alterations, generally associated with many tumors and 
specifically with colorectal tumors, are also significantly found in gastric cancer. In normal cells, 
pathway signaling is activated by the binding of WNT ligand to their Frizzled receptors and 
Lrp5/6 co-receptors leading to receptor phosphorylation and GSK3 inactivation. Without WNT 
signaling GSK3 acts in a complex with APC and AXIN constantly targeting ß-catenin, the 
transcriptional activator of WNT signaling, for destruction. Activated WNT signaling promotes 
cell proliferation and stem cell self-renewal through ß-catenin mediated transcription of target 
genes (Clevers et al., 2014). In gastric cancer, mutations in APC and CTNNB1 (encoding ß-
catenin), but also in another negative regulator, RNF43, are significant findings. Finally, 
mutations in chromatin remodelers, most frequently ARID1A, a component of the SWI/SNF 
complex, but also ARID1B and members of the MLL family are common. 
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1.2.4.5 SOX and Gastric Cancer 
Although SOX2 is well established to have oncogenic effects when expressed in tumors, often 
mediating CSC features, SOX2 in gastric cancer has been controversial. There are several studies 
supporting either an oncogenic role or a tumor suppressor role of SOX2 in gastric cancer 
(Carrasco-Garcia et al., 2016). In support of an oncogenic role, SOX2 downregulation in gastric 
cancer cell lines has been shown decrease proliferation and increase apoptosis, both in vivo and 
in vitro, and high SOX2 expression in human tumor samples has been found to correlate with 
increased lymph node metastasis and invasion (Hütz et al., 2014; Matsuoka et al., 2012). In 
contrast, others have found the opposite correlation where decreased SOX2 expression could be 
correlated with disease progression and increased expression with a survival advantage (Otsubo 
et al., 2008; Wang et al., 2015). Functionally, SOX2 overexpression in gastric cancer cell lines 
could induce cell cycle arrest and apoptosis and this via the upregulation of PTEN expression 
(Otsubo et al., 2008; Wang et al., 2015). Furthermore, in a recent mouse model of gastric 
adenoma, where Apc was homozygously deleted in SOX2 expressing cells, Sox2 deletion was 
found to increase the tumor burden. Mechanistically, the SOX2 anti-tumorigenic effect was 
achieved by counteracting the excessive WNT signaling induced by the loss of APC (Sarkar et 
al., 2016). 
SOX9, in addition to SOX2, is also expressed in normal gastric mucosa but has instead been 
revealed more clearly as oncogenic and its expression can be widely detected in gastric cancer 
tissue (Sashikawa Kimura et al., 2011). Its expression has been liked to H pylori infection, 
especially to the more virulent cagA and vacA expressing strains, and IL-1 expression in mice, as a 
consequence of H pylori infection induces SOX9 expression (Serizawa et al., 2016). In gastric cell 
lines, SOX9 is also increased by H pylori infection and has been found both to be regulated by 
and to be regulating ß-catenin expression, in addition to being induced by TNFα. The elevation 
of SOX9 after infection seems to be required for the proliferative and stem cell like properties 
induced by the bacteria, and inhibition of SOX9 instead leads to reduced proliferation and to 
apoptosis (Santos et al., 2016). 
Other SOX TFs have be been found in gastric cancer tissue, but their roles are more elusive, 
since most studies are clinical correlations and not functional experimentation. Briefly, SOX4 has 
been found to be up-regulated in many cancers compared to normal tissue, and so also in gastric 
cancer (Chen et al., 2015). Conversely, SOX11 has instead been found at lower expression levels 
in gastric cancer and with high promoter methylation (Qu et al., 2014; Xu et al., 2015). This 
methylation in cell lines can be removed by treating cells with the DNA methylation inhibitor 5-
Aza-dC and SOX11 levels restored, with a decrease in proliferation as a result (Xu et al., 2015). 
In addition to SOX11, low expression of SOX7 and SOX17 has also been correlated with poor 
survival and more advanced disease (Cui et al., 2014). Similarly to SOX11, SOX17 has been 
found heavily methylated, and restoring SOX17 levels decreased colony formation of gastric 
cancer cell lines (Oishi et al., 2012). 
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2 AIMS 
2.1 PAPER I 
All stem cells share the characteristics of self-renewal and the potential to differentiate into one 
or several specific cell-types. While sharing these features, stem cells of different organs have 
distinct gene expression profiles and potential when it comes to the production of progeny. 
However, it is unclear to what extent common features of stem cells from vastly different origins 
share the same regulatory mechanisms. The aim of Paper I was to clarify how SOX2 regulates 
stem cell properties in different organs. To answer this question, we used ChIP-seq together with 
RNA-seq to map the binding profiles of SOX2 and the distinct expression patterns in organs of 
ectodermal origin; cortex and spinal cord, as well as in organs of endodermal origin; lung and 
stomach. 
2.2 PAPER II 
Due to their proliferative capacity, stem and progenitor cells are always at risk of incorporating 
detrimental mutations that will remain in their lineage. Consequently, stem and progenitor cells 
have an increased susceptibility to oncogenic transformation. Many driver mutations have been 
defined and it is well established how gain or loss of function in several important genes leads to 
tumor initiation. Less well characterized are the mechanisms by which stem cells specifically 
protect themselves from, and react to, oncogenic transformation. The aim of Paper II was to 
investigate how the stem cell expression of SOX5, SOX6 and SOX21 (SOX5/6/21) affects 
tumor development. To address this question we used a mouse glioma model of brain cancer, 
and human primary glioblastoma cells, in which we could modulate the levels of SOX5/6/21. 
2.3 PAPER III 
Adult stem and progenitor cells of different tissues share the defining features of self-renewal 
and progeny differentiation, but exhibit distinct capacity and competence depending on the 
specific demands of the organ. While some adult stem cells divide rarely and generate a limited 
amount of progeny, as in the case of the CNS, others divide rapidly to provide large quantities of 
differentiated cells to support the function of the organ, such as in the gastrointestinal tract. 
Since, SOX21 is expressed in both of these stem and progenitor cell types, we asked in Paper 
III whether SOX21 exhibits similar functions in the rapidly proliferating cells of the stomach as 
in the slowly dividing cells of the brain. To address this we used bioinformatic approaches and in 
vitro based assays of SOX21 overexpression in human gastric cancer cell lines. 
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3 RESULTS AND DISCUSSION 
3.1 PAPER I 
To begin to answer our question about how SOX2 regulates stem cell characteristics in distinct 
cell populations, we first confirmed the stem and progenitor cell expression of SOX2 in mouse 
cortex, spinal cord, lung and stomach of E11.5 embryos and saw that it overlapped extensively 
with the proliferation marker Ki67. We next performed in vivo SOX2 Chromatin 
Immunoprecipitation and sequencing (ChIP-seq) on dissected E11.5 tissue from stomach and 
lung/esophagus, which we compared with E11.5 SOX2 ChIP-seq data from cortex and spinal 
cord (Hagey et al., 2016). Comparing the overlap of SOX2 binding regions (peaks), we found 
that although targeting a similar motif in all tissues, SOX2 binding was mostly cell type specific. 
However, the peaks that did overlap were mostly from tissues of the same germ layer (ectoderm 
or endoderm). Only 232 peaks were common between both endodermal and ectodermal tissue. 
Moreover, in a Principal Component Analysis, SOX2 binding in the cortex and spinal cord 
clustered together with the SOX2 binding pattern of ESC derived NPCs, whereas SOX2 binding 
in the stomach and lung/esophagus clustered with that of adult stomach. Interestingly, the 
SOX2 binding pattern of ESCs was equally related to that of ectodermal and endodermal tissues. 
Together these findings reveal that SOX2 mostly binds cell specific targets and that the binding 
is more similar in tissues of the same germ layer. 
Since SOX transcription factors are known to bind together with partner factors (Hagey et al., 
2016; Kondoh and Kamachi, 2009), we next sought to investigate whether this could be a 
reason for the distinct SOX2 binding patterns in the different tissues. To this end, we searched 
for the enrichment of binding motifs in neural, endodermal, or common peaks and found several 
candidates. Within the cortex peaks we found an enrichment of motifs for OTX1, in spinal cord 
PAX2, in stomach GATA4 and HNF1A and in the lung/esophagus FOXA1 and TEAD4. In 
peaks common to both neural and endodermal tissue, ZEB1 and ZBTB33 were found to be 
enriched. Although this does not mean that SOX2 actually co-binds with these factors, all of 
these transcription factors belong to families that have been shown to bind SOX proteins. 
Furthermore, they were also found to be appropriately expressed within the different tissues, 
suggesting that a functional relationship might be possible. To test this possibility, we performed 
immunoprecipitation of SOX2 together with the neural specific OTX1, the endoderm specific 
FOXA1 and the common ZEB1, all of which were found to interact with SOX2 in our 
overexpression assay. Interestingly however, only FOXA1 and ZEB1 seemed to bind SOX2 
directly without DNA, since DNaseI treatment completely abrogated the OTX1-SOX2 
interaction. While our results are indicative of a physical interaction, we cannot exclude the 
possibility of other factors binding in complex and thus only mediating a secondary interaction 
with our suggested partners. 
To test functional interaction between SOX2 and our candidate partners, we cloned peak 
regions, specifically or commonly bound, into luciferase reporter vectors and assayed activation 
in P19 cells with the different factors. Regions bound by SOX2 specifically in neural tissues 
could activate the reporter in response to SOX2 and OTX1 expression in an additive fashion. 
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Furthermore, endodermal specific SOX2 peak regions could activate reporter expression in 
response to either SOX2 or FOXA1, but did not exhibit any additive effect. In contrast, 
commonly bound peak regions could activate the reporter in response to SOX2 expression, an 
activation that was efficiently repressed by ZEB1, in line with its known repressor function 
(Spaderna et al., 2008). Together this data suggests a physical and functional interaction between 
SOX2 and TFs specifically in the different cell types, which may contribute to the cell-specific 
binding of SOX2 within these cells. 
In order to address how SOX2 binding affects gene expression profiles in different tissues, we 
next performed RNA-seq on FACS isolated SOX2-GFP+ cells from mouse E11.5 cortex, spinal 
cord, stomach and lung/esophagus. Similar to the SOX2 binding profiles, gene expression data 
showed more extensive overlap between tissues from the same germ layer. Correlating gene 
expression with SOX2 targeted genes (500 kb within the closest transcriptional start site) 
revealed that SOX2 binding was specifically enriched around genes expressed within the 
corresponding tissue. In agreement with this, GO analysis of specifically bound genes showed 
enrichment for terms appropriate for each tissue, such as “Pallium development” for genes bound in 
cortex, “Cell differentiation in spinal cord” for genes bound in spinal cord, “Embryo digestive tract 
development” for genes in stomach and “Lung alveolus development” for genes bound in 
lung/esophagus. Interestingly, genes that were commonly bound by SOX2 in neural and 
endodermal tissues showed a higher enrichment for GO terms such as “Regulation of stem cell 
proliferation” and “Regulation of stem cell differentiation”.  
Together this analysis indicated that differential SOX2 binding might be instructive and that 
SOX2 bound regions could act as cis regulatory modules (CRM) to direct cell specific gene 
expression. To test this, peak regions were inserted into GFP reporter vectors that were 
subsequently injected into zebrafish eggs, and screened for GFP expression. Strikingly, neural 
specific SOX2 bound regions activated GFP expression predominantly in the zebrafish CNS 
(71% of CRMs), whereas endoderm specific SOX2 bound regions predominantly activated 
expression in the zebrafish endodermal tissues (57% of CRMs). In contrast, commonly bound 
SOX2 regions activated GFP expression in both CNS and endodermal tissues (92% of CRMs). 
Collectively this shows that SOX2 bound regions in mouse neural and endodermal cells can 
drive gene expression in the corresponding tissue in the developing zebrafish, thus acting as 
CRMs. 
The interesting finding that genes commonly bound by SOX2 between neural and endodermal 
cells were enriched for genes important for stem cell proliferation resonates well with the notion 
that stem cell regulation is intimately linked to cell cycle regulation (Dalton, 2015; Gonzales et 
al., 2015; Pauklin and Vallier, 2013). It has previously been shown that SOX2 regulates the rate 
of proliferation in mouse embryonic cortex by repressing Ccnd1 expression and the Ccnd1 
promoter was indeed one of the 32 regions targeted by SOX2 in all four tissues examined 
(Hagey and Muhr, 2014). To find out whether cell cycle regulation is a common mechanism by 
which SOX2 regulates stem cells in different tissues, we characterized SOX2 levels and BrdU 
incorporation in mouse spinal cord and stomach. Cells expressing high levels of SOX2 
incorporated significantly less BrdU than did cells of low SOX2 expression. This was in 
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accordance with previous data from the cortex and true for both spinal cord and stomach 
(Hagey and Muhr, 2014). Interestingly, in the stomach there was a regional difference in the 
levels of SOX2 at E15.5 but not at E11.5, which reflected the proliferative rate of the respective 
regions. Furthermore, SOX2 could act instructively, as chick spinal cord electroporation or ex 
vivo electroporation of mouse stomach decreased BrdU incorporation significantly. On the other 
hand, downregulation of SOX2 levels, either by dominant negative SOXB1 or by shRNA against 
SOXB1, increased the incorporation of BrdU significantly. Interestingly, the SOX2 effect on 
proliferation was dependent on WNT pathway components. This is consistent with what has 
been shown for cortex, where SOX2 at high levels binds to low affinity sites and interacts with 
TCF/LEF to recruit the GRO/TLE repressor and where SOX2 at low levels instead binds 
distinct high affinity motifs in the Ccnd1 promoter moderating the recruitment of ß-catenin to 
TCF/LEF bound to this site (Hagey and Muhr, 2014). Since WNT signaling is a common driver 
of stem cell proliferation in multiple tissues (Clevers et al., 2014), one can speculate that this 
might be a common target of SOX2 to maintain slow proliferation in several types of stem cells. 
3.2 PAPER II 
To begin to study the function of SOX5/6/21 in brain tumor development, we first confirmed 
their expression in the adult mouse SVZ. In this niche, SOX5/6/21 co-labeled with the stem cell 
markers SOX2 and NESTIN in addition to the proliferation marker Ki67, and it can therefore 
be concluded that SOX5/6/21 are expressed in actively proliferating stem or progenitor cells. 
Next we tested the function of SOX5/6/21 by overexpressing SOX5, SOX6 or SOX21 in NSCs 
isolated from the SVZ. This uniformly led to a decreased rate of proliferation, as determined by 
EdU incorporation. As high levels of SOX5/6/21 have been shown to counteract tumorigenesis 
(Ferletta et al., 2011; Tchougounova et al., 2009; Wang et al., 2016; Xie et al., 2012), we wanted 
to determine SOX5/6/21 levels in the presence of oncogenes. Interestingly, transducing mouse 
SVZ cells in culture with the activated oncogenes AKT1 and H-RAS increased the protein levels 
of SOX5/6/21 compared to control transduced cells. In contrast, the protein levels of other 
stem cell expressed genes such as SOX2 or NESTIN remained unchanged, indicating that the 
increase in SOX5/6/21 expression was specific, and might serve as an attempt of the SVZ cells 
to evade oncogenic transformation. 
We next sought to verify this possibility by deleting Sox5/6/21 in mice stereotactically injected 
with oncogene-expressing viruses. In this mouse glioma model 10-15% of wt mice injected in the 
SVZ normally develop tumors. In contrast, mice in which a conditional deletion of Sox5, Sox6 or 
Sox21, or a combination of these, was induced at the same time as the viral oncogene injection, 
an increased tumor size and penetrance was observed, with the more severe phenotype in mice 
with a deletion of multiple Sox genes. Upon histological examination of the tumors, many high-
grade glioma features were found including increased cellular density and atypia, hemorrhage and 
microvascular proliferation. These features were more commonly associated with the 
combinatorial loss of Sox5/6/21 compared to the loss of individual Sox genes. Thus, 
SOX5/6/21 can prevent oncogene-driven tumor formation in a partly overlapping fashion. It is 
however important to note that no hyperproliferative phenotype was found in mice with 
conditional deletion of Sox5/6/21 in the absence of oncogenic expression. Consistently, 
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although loss of function studies have revealed specific roles for SOX5, SOX6 and SOX21 in 
the specification, differentiation and maturation of neurons and oligodendrocytes (Azim et al., 
2009; Lai et al., 2008; Sandberg et al., 2005; Stolt et al., 2006), no general role for these SOX 
proteins in regulating proliferation has been revealed in the developing or adult CNS. Therefor, it 
is interesting to note that the ability of SOX5/6/21 to block excessive proliferation is perhaps 
only revealed under tumorigenic conditions.  
To further establish how the loss of Sox5/6/21 affects oncogene-expressing cells, SVZ cells 
from mice of different genotypes newly injected with AKT/H-RAS/Cre were isolated and grown 
as spheres in culture. Cells from Sox5/6, Sox21 or Sox5/6/21 mutant mice formed significantly 
more spheres that grew bigger in size compared to cells from wt mice. In line with this result, we 
also found that Sox21 and Sox5/6/21 mutant spheres incorporated EdU at a higher level and 
were labeled more extensively by Ki67, thus indicating an increased proliferative rate, as 
compared to wt spheres. Furthermore, GO analysis of RNA-seq data of genes upregulated in 
Sox5/6/21 mutant versus wt spheres, revealed significant enrichment of terms for proliferation 
such as “Mitotic cell cycle”, “Cell cycle” and “Cell division”. This was in contrast to downregulated 
genes, which instead showed high enrichment for terms associated with differentiation such as 
“Neurogenesis”, “Gliogenesis” and “Axon guidance pathway”. Moreover, comparing the differentially 
expressed genes in oncogene-expressing cells with and without Sox5/6/21 with genes 
differentially expressed in human GBM versus low grade glioma, a similar pattern emerged 
where important cell cycle promoting genes were commonly up-regulated and genes important 
for differentiation and tumor suppression were commonly downregulated. Thus, the same 
cellular mechanisms that induce more malignant human gliomas are active in the oncogene-
induced mouse cells lacking Sox5/6/21. 
An essential mechanism of cell cycle regulation is the Cyclin/CDK-RB axis in which RB blocks 
cell cycle progression unless phosphorylated by Cyclin/CDK complexes. An additional 
regulatory level exists in the CDK inhibitors, which counteract Cyclin/CDK activity, thus 
inhibiting proliferation. To find out how this pathway was affected, and since most of these 
factors are regulated at a post-translational level rather than a transcriptional level, we next 
evaluated their presence in our oncogene-expressing spheres by western blot. Loss of Sox5/6/21 
severely increased the protein levels of several Cyclins. Furthermore, although total RB levels did 
not change, there was a sharp increase in the levels of the phosphorylated inactive form of RB, 
which was most prominent in the triple Sox5/6/21 mutant cells. Moreover, although the levels 
of the CDK inhibitors p21 and p27 and the tumor suppressor p53 did increase upon expression 
of the oncogenes in wt cells compared to GFP control, this upregulation was efficiently 
suppressed when Sox5/6/21 were deleted. 
Since the loss of a p53 and CDK inhibitor response to oncogenes could be an underlying 
mechanism for the excessive proliferation and the malignant transformation of the mutant cells, 
we next wanted to test whether we could block the observed phenotypes by increasing their 
levels. Indeed, restoring the levels of p21, p27 or p53 in spheres or in animals lacking Sox5/6/21 
significantly decreased the proliferative capacity and the tumor forming ability of the oncogenes. 
 44 
Thus, the anti-tumorigenic response mounted by SOX5/6/21 seems, at least in part, to be 
achieved by increasing CDK inhibitors and p53 protein levels. 
Having established the protective effect of SOX5/6/21 during oncogene expression, we next 
asked whether SOX5/6/21 could also exhibit an anti-tumorigenic effect in already transformed 
cells. Lenti-viral overexpression of SOX5/6/21 efficiently decreased proliferation of human 
primary glioblastoma cells compared to GFP control. Furthermore, intracranial injection of 
SOX5/6/21 expressing cells into NOD-SCID mice completely blocked their capacity to form 
tumors compared to GFP-expressing control cells. This striking effect on human primary 
glioblastoma cells led to the question whether there is a similar negative relationship between 
SOX5/6/21 expression and malignancy grade in human glioma. To test this we used publically 
available RNA expression data from human low grade glioma (grade II and III) and high grade 
glioma (grade IV) and compared the expression of SOX5/6/21 in these two sets. Consistently, 
the expression levels of SOX5/6/21 normalized against PCNA, were all significantly decreased 
in high versus low grade glioma. Together this shows that SOX5/6/21 have an anti-tumorigenic 
effect not only during tumor initiation, but also in full-blown disease. 
In order to reveal the molecular pathways in malignant cells targeted by SOX5/6/21 
upregulation, we next performed RNA-seq on human primary gliomblastoma cells transduced 
with SOX5/6/21 or GFP control. Thousands of gene were found to be differentially expressed 
and among the genes significanly downregulated there was an enrichment of GO terms for 
proliferation such as “Mitotic cell cycle”, “Nuclear division” and “RB in cancer”. In contrast, 
upregulated genes instead showed significant enrichment for terms associated with tumor 
suppressor responses, including “Apoptotic process”, “Cellular response to stress”, “Direct p53 effector” 
and “Senescence and autophagy”. Consistantly, the CDK inhibitors and p53 were upregulated by 
SOX5/6/21 in primary glioblastoma cells at a protein level. Furthermore, assessing the 
functional tumor suppressor responses apoptosis and senescence revealed a significant increase 
in both of these processes after SOX5/6/21 expression in human primary glioblastoma cells. 
Since both apoptosis and senescence can be induced by increased levels of the tumor suppressor 
p53, we next asked whether the increase in these processes was dependent on p53. Blocking p53 
with shRNA completely blocked both apoptosis and senescence induced by SOX21 in human 
primary glioblastoma cells. Moreover, while the overexpression of SOX21 in human primary 
glioblastoma cells did not reveal any SOX21 binding in the vincity of the TP53 gene, as 
determined by ChIP-seq, or any upregulation of TP53 expression, as determined by RNA-seq, 
we could show that it did lead to a decrease in p53 protein turn-over. This stabilization was 
associated with increased phosphorylation of p53 and decreased protein levels of the negative 
p53 regulator MDM2. Taken together, these data show that SOX21 can initiate a tumor 
suppressor response in malignant cells by counteracting p53 protein turn-over. 
In summary, we have shown that SOX5/6/21 have partly overlapping activities suppressing 
oncogene-induced transformation of brain stem and progenitor cells, and that their increased 
expression in fully malignant cells can re-activate a tumor suppressor response. This is a novel 
mechanism by which stem and progenitor cells in the brain could potentially evade malignant 
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transformation driven by oncogenic insult, and thus promote well established tumor suppressor 
responses. 
3.3 PAPER III 
As targeted deletion of Sox21 in Paper II revealed a significant tumorigenic phenotype in mouse 
neural stem cells under oncogenic pressure, we aimed to investigate whether the anti-tumorigenic 
function of SOX21 could be a more general mechanism of tumor suppression and not only 
brain stem cell specific. To do this, we started by examining the expression pattern of SOX21 in 
adult human gastric epithelium, a tissue in which SOX21 mRNA expression has been reported. 
In the corpus region, which is the more proximal part of the ventricle, we could find strong 
immunolabeling for SOX21 in the glandular cells of the gastric pit and the isthmus. In this region 
cells were also labeled with antibodies against SOX2, and Ki67. Using double 
immunofluorescence we could see that SOX21 expression overlapped with that of SOX2 in the 
pit and isthmus region and with Ki67 in the isthmus region. Therefore, SOX21 seems to be 
expressed in proliferating SOX2 positive cells in the normal human gastric epithelium, in 
addition to differentiated post-mitotic cells.  
As SOX21 was seen in Paper II to be downregulated in high grade glioma compared to lower 
grade glioma, we wanted to see whether this inverse relationship with malignancy was also true 
for SOX21 in gastric cancer. Publically available RNA-seq data from gastric adenocarcinomas 
and normal gastric tissue samples were compared. We found significantly lower levels of SOX21 
mRNA in the malignant tissue and this reduction was true for all four molecular phenotypes. 
Interestingly, within this large dataset there were some genetic alterations of the SOX21 gene, 
including homozygous deletion, missense mutation and amplification, where the last one was 
most common (3%). However, regardless of genetic amplification, the mRNA levels of SOX21 
were still lower in these tumor samples compared to normal tissue, indicating that other 
mechanisms are acting to keep the SOX21 expression at low levels. Since CpG island 
methylation is a potent regulator of gene expression, we wanted to explore this by comparing 
methylation levels of the SOX21 promoter in malignant versus normal tissue. However, SOX21 
promoter methylation was not significantly changed. 
To confirm the human gastric tissue expression of SOX21 in mouse, we performed 
immunolabeling of SOX21 in mouse embryonic stomach. SOX21 expression follows that of 
SOX2 and is expressed at high levels in the stomach at E11.5 and E13.5, at lower levels in the 
esophagus and not at all in the small intestine. RNA-seq of adult mouse gastric epithelium 
revealed expression of several Sox genes, with the highest levels of gastric epithelium and cancer 
relevant Sox9 and Sox2 together with, the in the stomach so far uncharacterized, Sox21 and 
Sox13. In a more detailed analysis of mouse gastric antrum we found that Sox21 mRNA located 
to the isthmus region, while the protein was found in a more widespread manner including most 
cells from the base to the pit. This protein expression was further seen to overlap extensively 
with that of, in mouse previously characterized, gastric stem cell marker SOX2, and with 
proliferation marker Ki67.  
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So far, no gastric phenotype has been reported after targeted deletion of Sox21. Therefore, to 
specifically assess this, we induced Sox21 deletion in adult mice using tamoxifen-inducible Cre 
expression in the Sox2 locus. One month after tamoxifen induction, no difference in EdU 
incorporation between targeted glands of Sox21 homozygous or heterozygous animals could be 
detected, indicating that Sox21 expression is dispensable for normal gastric homeostasis. 
As the reduced expression of SOX21 in gastric cancer tissue compared to normal tissue could 
indicate a loss of anti-tumorigenic activity in these cells, we wanted to find out whether re-
establishing SOX21 expression in gastric cancer cells could lead to an induction of an anti-
tumorigenic response. Three human gastric cancer cell lines with low expression of SOX21, were 
virally transduced with either SOX21 or GFP control. All three cell lines showed decreased 
proliferation after transduction with SOX21 as seen by EdU incorporation. In a subsequent 
RNA-seq analysis we found thousands of genes to be regulated by SOX21, many of which were 
implicated in cell cycle regulation as GO terms such as “Negative regulation of cell proliferation” was 
enriched within upregulated genes in the KATOIII cell line, and “Mitotic cell cycle process” was 
enriched within the downregulated genes in the NCI-N87 cell line. Furthermore, enrichment of 
GO terms including “Programmed cell death” were found within the upregulated genes of NCI-N87 
and AGS cell lines.  
Since apoptosis is a fundamental tumor suppressor response, we next sought to find out whether 
SOX21 could directly induce this process in the gastric cancer cell lines. Six days after 
transduction, SOX21 significantly increased the levels of AnnexinV in NCI-N87 and AGS cells, 
but not in KATOIII cells. As we could show in Paper II that the apoptotic phenotype seen in 
human primary glioblastoma cells was mediated by the stabilization of p53, we then wanted to 
find out whether this could also be the mechanism by which SOX21 could induce apoptosis in 
gastric cancer cells. Five days after SOX21 transduction, a small increase in p53 could be seen in 
the AGS cell line, but none in the NCI-N87 or in the KATOIII cells. It is interesting to note that 
while the AGS cell line expresses wild type p53, the NCI-N87 cell line harbors a common TP53 
missense mutation and the KATOIII cell line a homozygous deletion of the TP53 locus. 
Nevertheless, although p53 seems to be an important factor for inducing an apoptotic response 
in AGS cells compared to KATOIII cells, the NCI-N87 cells are still able to mount an apoptotic 
response without increasing the already high levels of mutant p53. In conclusion, restoring 
SOX21 levels in human gastric cancer cells can induce an anti-tumorigenic response, which 
might in part be mediated by increasing wt p53 levels. 
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4 CONCLUSION AND FUTURE DIRECTIONS 
With the work in this thesis we have illustrated how one TF, SOX2, can act in different stem cell 
populations protecting their status by regulating common features and features specific to each 
stem cell lineage and their identity, by binding to specific CRMs. In addition, apart from 
protecting stem cell maintenance, we found that another set of TFs from the same family, 
SOX5/6/21 also act to protect stem cells, but in a different setting, being revealed only under 
the stress of oncogenes. As it is becoming increasingly clear that cell cycle control, DNA damage 
pathways and stem cell regulation are intimately linked (Dalton, 2015; Gonzales et al., 2015; 
Pauklin and Vallier, 2013), it might not be surprising that TFs previously known to regulate 
features within stem cells during development could also protect cells against excessive 
proliferation induced by oncogenes. Interestingly, the regulation of SOX protein levels and the 
regulatory function achieved by SOX proteins appear not to be controlled at the transcriptional 
level in the oncogenic setting. Although many SOX TFs are transcriptionally regulated by the 
activity of specific enhancers (Boyer et al., 2005; Uchikawa, 2008), SOX protein regulation is 
also well established and many SOX TFs have been found to be regulated by a variety of 
different post-translational modification (Lim et al., 2017; Liu et al., 2013; Suryo Rahmanto et 
al., 2016). What requires further investigation is how SOX proteins modulate cell functions in a 
non-transcriptional manner. The fact that SOX21 seems to function in a similar manner in stem 
cells of the brain and stomach, justifies why more attention should be paid to the question of 
how SOX21 could be protecting stem cells from oncogenic transformation. Further studies into 
the mechanisms activating increased protein levels of SOX21 during stress, and also the direct 
targets of SOX21, will be interesting paths to pursue. 
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